header logo image


Page 583«..1020..582583584585..590600..»

Insights on the Cell Expansion Industry in North America to 2027 – by Product, Cell Type, Application, End-user and Country – GlobeNewswire

April 24th, 2020 5:47 pm

Dublin, April 24, 2020 (GLOBE NEWSWIRE) -- The "North America Cell Expansion Market to 2027 - Regional Analysis and Forecasts by Product; Cell Type; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

The cell expansion market in North America is anticipated to reach USD 14,697.41 million by 2027 from USD 4,522.07 4 million in 2019; it is projected to grow at a CAGR of 15.9% during 2020-2027. The growth of the market is attributed to the increasing prevalence of cancer, rising number of new product launches, and increasing inclination of patients toward regenerative and personalized medicines. Also, growing R&D expenditure on cancer research is likely to have a positive impact on the growth of the market in the coming years. In addition, technological advancements in the pharmaceuticals industry and extensive developments in drug discovery are likely to stimulate the growth of cell expansion market in North America during the forecast period.

Cell expansion is the large-scale artificial production of daughter cells from a single cell, and the process is carried out to support the medical research. It plays a critical role in exploring a wider range of benefits and applications of fully differentiated stem cell cultures for their use in therapeutics, drug screening, or advanced research.

R&D is a significant part of a majority of pharmaceutical and biotech companies; they focus on R&D to come up with new molecules with the most significant medical and commercial potential for various therapeutic applications. The companies invest big amounts in these activities to deliver innovative, high-quality products to the market. Moreover, as per the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expense of biopharmaceutical companies surged from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015.

Several government organizations are working on enhancing the detection methods and treatment procedures of cancer in the region. The National Cancer Institute (NCI) spends on various categories of the treatment, including specific cancer sites, cancer types, and cancer-related diseases, as well as types of NCI research mechanisms. The NCI allocated the funds of ~US$ 208.4 million for cell expansion research in 2017 from their total budget of US$ 5,636.4 million in that year for cancer research studies. Therefore, the growing R&D expenditure on cancer research by these companies is expected to provide them with opportunities for business expansion.

The North American cell expansion market has been segmented on the basis of cell type into human cells and animal cells. The human cells segment held a larger share of the market in 2018, and it is also projected to register a higher CAGR in it during the forecast period. Rise in research activities for the treatment of cancer is expected to offer considerable growth opportunities for the human cell expansion market players.

A few of the important secondary sources referred to for preparing this report on the cell expansion market are World Health Organization (WHO), Food and Drug Administration (FDA), Canadian Cancer Society, Centers for Disease Control and Prevention (CDC), and American Cancer Society.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 North America Cell Expansion Market - By Product1.3.2 North America Cell Expansion Market - By Cell Type1.3.3 North America Cell Expansion Market - By Application1.3.4 North America Cell Expansion Market - By End User1.3.5 North America Cell Expansion Market - By Country

2. North America Cell Expansion Market- Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. North America Cell Expansion Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 Cell Expansion Market - North America PEST Analysis4.3 Expert Opinion

5. North America Cell Expansion Market - Key Market Dynamics5.1 Key Market Drivers5.1.1 Patient shift towards regenerative medicines5.1.2 Increasing number of patients suffering with cancer5.2 Key Restraints5.2.1 Risk of contamination associated with the cell expansion process5.3 Key Market Opportunities5.3.1 Growing R&D Expenditure for Cancer Research5.4 Future Trend5.4.1 Extensive development in drug discovery5.5 Impact Analysis

6. Cell Expansion Market - North America Analysis6.1 North America Cell Expansion Market Revenue Forecasts and Analysis6.2 Positioning Of Key Players

7. North America Cell Expansion Market Analysis And Forecasts To 2027 - Product7.1 Overview7.2 North America Cell Expansion Market, By Product 2018 & 2027 (%)7.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Product (US$ Mn)7.2.1.1 North America Consumables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.1.1 North America Disposables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.2 North America Instruments Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.3 Consumables7.3.1 Overview7.3.2 North America Consumables Market Revenue and Forecast to 2027 (US$ Mn)7.3.3 Reagents, Media & Serum7.3.3.1 Overview7.3.3.2 North America Reagents, Media & Serum Market Revenue and Forecast to 2027 (US$ Mn)7.3.4 Disposables7.3.4.1 Overview7.3.4.2 North America Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.3 Culture Tissue Flasks7.3.4.3.1 Overview7.3.4.3.2 North America Culture Tissue Flasks Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.4 Bioreactor Accessories7.3.4.4.1 Overview7.3.4.4.2 North America Bioreactor Accessories Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.5 Other Disposables7.3.4.5.1 Overview7.3.4.5.2 North America Other Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.4 Instruments7.4.1 Overview7.4.2 North America Instruments Market Revenue and Forecasts to 2027 (US$ Mn)7.4.3 Cell Expansion Supporting Equipment7.4.3.1 Overview7.4.3.2 North America Cell Expansion Supporting Equipment Market Revenue and Forecast to 2027 (US$ Mn)7.4.4 Bioreactors7.4.4.1 Overview7.4.4.2 North America Bioreactors Market Revenue and Forecast to 2027 (US$ Mn)7.4.5 Automated Cell Expansion Systems7.4.5.1 North America Automated Cell Expansion Systems Market Revenue and Forecast to 2027 (US$ Mn)

8. North America Cell Expansion Market Analysis And Forecasts To 2027 - Cell Type8.1 Overview8.2 North America Cell Expansion Market, By Cell Type 2018 & 2027 (%)8.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Cell Type (US$ Mn)8.3 Human Cells8.3.1 Overview8.3.2 North America Human Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.3 Adult Stem Cells8.3.3.1 Overview8.3.3.2 North America Adult Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.4 Induced Pluripotent Stem Cells8.3.4.1 Overview8.3.4.2 North America Induced Pluripotent Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.5 Embryonic Stem Cells8.3.5.1 Overview8.3.5.2 North America Embryonic Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.6 Differentiated Cells8.3.6.1 Overview8.3.6.2 North America Differentiated Cells Market Revenue and Forecast to 2027 (US$ Mn)8.4 Animal Cells8.4.1 Overview8.4.2 North America Animal Cells Market Revenue and Forecast to 2027 (US$ Mn)

9. North America Cell Expansion Market Analysis- By Application9.1 Overview9.2 North America Cell Expansion Market, By Application 2018 & 2027 (%)9.3 Regenerative Medicine and Stem Cell Research9.4 Cancer and Cell-based Research9.5 Other Applications

10. North America Cell Expansion Market Analysis- By End User10.1 Overview10.2 North America Cell Expansion Market, By End User 2018 & 2027 (%)10.3 Biopharmaceutical And Biotechnology Companies10.4 Research Institutes10.5 Cell Banks10.6 Other End Users

11. Cell Expansion Market Revenue And Forecasts To 2027 - Geographical Analysis11.1 North America Cell Expansion Market, Revenue and Forecast to 202711.1.1 North America Cell Expansion Market, Revenue and Forecast to 2027 (US$ Mn)11.1.2 North America Cell Expansion Market, Revenue and Forecast to 2027, By Product (US$ Mn)11.1.2.1 North America Consumables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.1.1 North America Disposables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.2 North America Instruments Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.3 North America Cell Expansion Market, Revenue and Forecast to 2027, By Cell Type (US$ Mn)11.1.3.1 North America Human Cell Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.4 North America Cell Expansion Market, Revenue and Forecast to 2027, By Application (US$ Mn)11.1.5 North America Cell Expansion Market, Revenue and Forecast to 2027, By End User (US$ Mn)11.1.6 North America Cell Expansion Market, Revenue and Forecast to 2027, By Country (%)11.1.7 US11.1.8 Canada11.1.9 Mexico

12. North America Cell Expansion Market- Industry Landscape12.1 Overview12.2 Growth Strategies In The Cell Expansion Market, 2017-201912.3 Organic Growth Strategies12.3.1 Overview12.3.1.1 Recent Organic Developments By Players In The Cell Expansion Market12.4 Inorganic Growth Strategies12.4.1 Overview12.4.2 Recent Developments By Players In The Cell Expansion Market

13. Global Cell Expansion Market-Key Company Profiles13.1 BD13.1.1 Key Facts13.1.2 Business Description13.1.3 Financial Overview13.1.4 Product Portfolio13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Merck KGaA13.3 Thermo Fisher Scientific, Inc.13.4 Terumo Corporation13.5 General Electric Company13.6 Corning Incorporated13.7 Miltenyi Biotec13.8 Danaher13.9 Lonza13.10 STEMCELL Technologies, Inc.

14. Appendix14.1 About the Publisher14.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/gq37sj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:
Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - GlobeNewswire

Read More...

The global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028 -…

April 24th, 2020 5:47 pm

NEW YORK, April 22, 2020 /PRNewswire/ --

KEY FINDINGSThe global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028. The prominent drivers of market growth are estimated to be the rising big data in the healthcare industry, the growing use of AI in genetics, the emergence of personalized medicine in tests for clinical decision making, along with the creation of a real-time monitoring system due to AI.

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

MARKET INSIGHTSThe utilization of AI in healthcare entails the use of software and algorithms for estimating the human perception for analyzing complex medical data, along with the relationship between treatments or prevention techniques and patient outcomes.The growing demand for real-time monitoring system is one of the key aspects propelling the growth of the global artificial intelligence in healthcare market.

The real-time monitoring devices like health monitoring devices or indicators track real-time health data of patients, which is increasing the demand for AI in healthcare.The devices also drive the relevancy of data interpretation and aid in reducing the time the patients spend in piecing data output.

In healthcare, the devices help in detecting and preventing undesirable patient outputs. The growing number of mobile devices integrated with artificial intelligence assists in the prediction of future outcomes with regard to health, which further benefits market growth.Medical practitioners are reluctant to adopt AI-based technologies, and this is restraining the growth of the market.The reluctance is because of the lack of data that identifies healthcare decisions.

Also, from a diagnostics point of view, AI systems fare less in terms of efficiency in comparison to conventional methods.The companies in the market are competing against each other by providing the same characteristics and similar prices.

The competitive rivalry is projected to be high during the forecast period.

REGIONAL INSIGHTSThe geographical segmentation of the global artificial intelligence in healthcare market includes the analysis of Europe, North America, Asia Pacific, and the rest of the world.Inkwood Research estimates the Asia Pacific region to be the fastest-growing region by the end of the forecast period.

The invention of new technologies, the presence of countries like China, Japan, Australia, and India, and the thriving artificial intelligence market, are the factors propelling the growth of the market.

COMPETITIVE INSIGHTSSome of the prominent companies operating in the market are Enlitic Inc, Next IT Corporation, Recursion, Welltok, GE Healthcare, Microsoft Corporation, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned1. DEEP GENOMICS INC2. ENLITIC INC3. GE HEALTHCARE4. GENERAL VISION INC5. GOOGLE6. IBM CORPORATION7. ICARBONX8. INTEL CORPORATION9. MICROSOFT CORPORATION10. NEXT IT CORPORATION11. NVIDIA CORPORATION12. ONCORA MEDICAL13. RECURSION PHARMACEUTICALS INC14. STRYKER CORPORATION15. WELLTOK INC

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-artificial-intelligence-in-healthcare-market-is-set-to-register-growth-projecting-a-cagr-of-38-05-during-the-forecast-period-2020-2028--301045674.html

SOURCE Reportlinker

More:
The global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028 -...

Read More...

7 Beautiful Biotech Stocks to Buy Here – Investorplace.com

April 24th, 2020 5:47 pm

Its pretty hard to ignore the impact of Covid-19 on the global and domestic economy. But the shutdown in the U.S. economy, while swift, was also swiftly managed by the administration and Congress, as well as the Federal Reserve.This has helped buoy the markets after a precipitous initial drop. And it has allowed enough time for investors to process everything that has happened and reset their expectations looking away from certain risks and into cleaning-supply companies and biotech stocks.

Previous to Covid-19, there was the feeling the economy was nearing recession sometime this year. Now were in one.

However, this remains an uneven market. Big stocks like Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) are doing even better under these difficult conditions. But other consumer stocks arent.

Thats why I wanted to talk about an opportunity that doesnt have to do with consumer-driven stocks the seven beautiful biotech stocks to buy here. These companies are set up to endure long drug approval processes that happen over good times and bad.

Theyre built to be immune from general market forces, especially the big one these days consumer spending and to benefit from powerful technology thats popping up in all kinds of industries.

Source: Catalin Rusnac/ShutterStock.com

CRISPR is a Swiss biotech that is one of the leaders in CRISPR technology. This is a new and fast-growing field. CRISPR (it stands for clustered regularly interspaced short palindromic repeats) is a DNA segment containing short repetitions of base sequences.

By using these, scientists are learning to identify where there is a break in the pattern that may signal a disease and then repair (or edit) that sequence. This is a revolutionary concept in treating disease, since it is the first step toward personalized medicine.

Currently the research is hoping to build treatments to help battle many different cancers and other diseases. But eventually the technology can be applied to a much broader field of needs.

The company is well funded and will continue to make a difference, even sequencing Covid-19.

The stock is up 37% in the past year and over 30% in the past month.

Source: Pavel Kapysh / Shutterstock.com

Acceleron is a biopharmaceutical company that has been around since 2003. Last year was a wild ride for the firm, and the volatility continued into 2020.

In September, one of its drugs in trials was rejected by the FDA and the stock tanked. Then, shortly after that, its drug luspatercept, which treats a rare blood disorder, was approved.

And then, in late January, data from a Phase 2 trial of another drug it has in the approval process for pulmonary arterial hypertension (PAH), showed significant positive results in treating the disorder. This is the kind of situation that can attract big buying pressure on Wall Street of the kind I want to see inGrowth Investor.

Needless to say, the stock is now up 134% in the past year, and 38% in the past month.

One of its largest shareholders is Bristol Myers Squibb (NYSE:BMY). Acceleron had been doing a lot of work with Celgene when BMY bought Celgene. This is a great partnership to have when looking to market, manufacture and distribute these new drugs.

Source: Shutterstock

Neurocrine Bioscienceshas been in business for over 25 years and specializes in developing treatments for people suffering with neurological, endocrine and psychological disorders.

It currently has treatments for tardive dyskinesia and endometriosis. It has candidates for Parkinsons, uterine fibroids and congenital adrenal hyperplasia. Last year, there was talk that Biogen (NASDAQ:BIIB) may have been looking at NBIX as an acquisition to build on its own work in some of these sectors.

Its a solid company that has a good balance of revenue-generating drugs and a solid, focused drug pipeline. Neurocrine has a unique niche and will remain an attractive takeover target for larger pharmaceutical companies and biotechs.

The stock is up 17% for the past year, and 20% in the past month.

Source: Jarretera / Shutterstock.com

Galapagos is a Belgian company that specializes in small molecule and antibody therapies.

It was a solid performer and has been around for over 20 years. But its big break happened last year when Gileadapproached the company and offered it a $5 billion partnership deal. This brought the stock to the attention of many U.S. investors who hadnt paid much attention to it.

And by December, that partnership paid off. GILD filed with FDA for speedy review of filgotinib, a potential blockbuster drug that GLPG developed and had in Europe in Japan but not the U.S. The U.S. is the market where the money is made, since pricing is far more dynamic than in other countries.

The approval came in December. And this could mean big things for both companies. But since then, Covid-19 has taken the spotlight and Gileads remdesivir has been all the buzz.

GLPG stock is up over 80% in the past 12 months, and almost 45% in the past month. Its management has also been wise enough to partner with a genomics company that provides whats sometimes nicknamed the mother of all technologiesto help discover new treatments and drug combinations.

Source: Eyesonmilan / Shutterstock.com

Incyte has been around since the early 1990s and is good-sized biopharmaceutical company with a $21 billion market capitalization.

Currently it has two drugs in the marketplace, one of those is in the US. Its big drug is Jakafi (ruxolitinib), which treats a rare form of blood cancer and is also approved to manage acute graft-versus-host disease in adults.

It also has a drug that it acquired from ARIAD Pharmaceuticals for European distribution. Its Iclusig (ponatinib) is used to treat leukemia, and INCY stock hopes to make the drug available in the U.S. after approval from the FDA.

Incyte also has a good number of drugs in the pipeline and has the financial wherewithal to keep moving them forward, even now.

The stock is up 36% in the past 12 months, and over 60% in the past month.

Source: madamF / Shutterstock.com

Regeneron is one of those biotech stocks that has been a direct Covid-19 beneficiary.

It has a number of drugs in the market and around 30 drugs in its pipeline. It has been around since 1988 and has a $62 billion market cap, so this is no one-trick pony rolling the dice on a potential blockbuster. It has built its reputation over time, delivering solid drugs in important sectors.

But the added juice at this point is its arthritis drug Kevzara that it co-markets with Sanofi (NASDAQ:SNY). It has been given to patients in China and New York (the co-founder of Regeneron is from Queens) but the testing isnt broad enough to deliver any conclusive information.

Obviously, the bet on Kevzara being a treatment is just that, a bet. But it has brought more attention to REGN, which is a quality pharma. And Regeneron also has its eye on the big picture of next-generation technology to supercharge its genomics research at the Regeneron Genetics Center.

The stock is up almost 62% in the past year and up 22% in the past month.

Source: Michael Moloney / Shutterstock.com

Gilead has been a big name among biotech stocks for a long time. It was a key player in finding a treatment for HIV/AIDS. And was also a pioneer in finding a highly effective once-a-day regimen for hepatitis C.

While it still makes a good amount of money from these blockbusters, it hadnt had a big hit in a while and the stock flat-lined as investors wondered if its best days were behind it.

But it has made some interesting acquisitions and partnerships in the past couple years, one of those being with Galapagos.

And now, remdesivir is in two Phase 3 clinical trials as a treatment for Covid-19. This, along with the promising partnership with GLPG stock thats already delivering results, promises that GILD could beback in the running with two potential blockbusters. Even one would be great news.

The stock is on the move, up 30% in the past 12 months, and 13% in the past month. And it is still off its 2015 highs, so theres plenty of headroom if either or both these drug live up to their promise.

Gilead is one of the big kahunas in this space, and now a household name, thanks to the fight against Covid-19. It, too, is partnering with smaller labs to harness the power of the game-changing technology of our time: artificial intelligence (AI).

If artificial intelligence sounds futuristic, even far-fetched well, keep in mind, youre already using it every day. If youve ever usedAlphabets(NASDAQ:GOOG, NASDAQ:GOOGL) Google Assistant orApples(NASDAQ:AAPL) Siri if youve hadNetflix(NASDAQ:NFLX) recommend a movie orZillow(NASDAQ:Z) recommend a house even an email spam filter then youve used artificial intelligence.

In this new world of AI everywhere, data becomes a hot commodity.

As scientists find even more applications for artificial intelligence from hospitals to retail to self-driving cars its incredible to imagine how much data will be involved.

To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system. As one AI researcher from the University of South Florida puts it, data is the new oil.

To cash in, youll want the company that makes the brain that all AI software needs to function, spot patterns and interpret data.

Its known as the Volta Chip and itswhat makes the AI revolution possible.

You dont need to be an AI expert to take part.Ill tell you everything you need to know, as well as my buy recommendation, inmy special report forGrowth Investor,The A.I. Master Key. The stock is still under my buy limit price so youll want to sign up now. That way, you can get in while you can still do so cheaply.

Click here for a free briefing on this groundbreaking innovation.

Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system withreturns rivaling even Warren Buffett. In his latest feat, Louis discovered the Master Key to profiting fromthe biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.

Read the rest here:
7 Beautiful Biotech Stocks to Buy Here - Investorplace.com

Read More...

genetics – Kids | Britannica Kids | Homework Help

April 24th, 2020 5:46 pm

In the 1850s and 1860s an Austrian monk named Gregor Mendel studied pea plants in his garden. He found that there were rules for how traits passed from one generation of pea plants to the next. The rules are the same for every plant and animal. During his lifetime no one understood how important these findings were.

In 1900 people rediscovered Mendels work. From then on, the new science of genetics grew rapidly. Scientists began to use it to help explain the theory, or idea, of evolution. An English scientist named Charles Darwin had put forth the theory in the 1850s. It describes how species adapt to their environment and how new species form.

In 1953 James Watson of the United States and Francis Crick of England discovered the structure of DNA. Their studies helped scientists understand how genes work and how they make copies of themselves.

By the mid-1970s, scientists had learned how to locate, remove, and insert specific genes in DNA. This work is called genetic engineering. By the 1990s scientists could clone animals, or produce animals that have exactly the same DNA as another animal. In 1996 researchers in Scotland produced the first clone of an adult mammala sheep. Some scientists worked toward cloning human beings. But others saw this work as dangerous and wrong.

In 2003 a team of researchers finished a project to identify and locate all the genes in all human DNA. The results will help scientists in the study of human biology and medicine.

Original post:
genetics - Kids | Britannica Kids | Homework Help

Read More...

Genetics: The Study of Heredity | Live Science

April 24th, 2020 5:46 pm

Genetics is the study of how heritable traits are transmitted from parents to offspring. Humans have long observed that traits tend to be similar in families. It wasnt until the mid-nineteenth century that larger implications of genetic inheritance began to be studied scientifically.

Natural selection

In 1858, Charles Darwin and Alfred Russell Wallace jointly announced their theory of natural selection. According to Darwins observations, in nearly all populations individuals tend to produce far more offspring than are needed to replace the parents. If every individual born were to live and reproduce still more offspring, the population would collapse. Overpopulation leads to competition for resources.

Darwin observed that it is very rare for any two individuals to be exactly alike. He reasoned that these natural variations among individuals lead to natural selection. Individuals born with variations that confer an advantage in obtaining resources or mates have greater chances of reproducing offspring who would inherit the favorable variations. Individuals with different variations might be less likely to reproduce.

Darwin was convinced that natural selection explained how natural variations could lead to new traits in a population, or even new species. While he had observed the variations existent in every population, he was unable to explain how those variations came about. Darwin was unaware of the work being done by a quiet monk named Gregor Mendel.

Inheritance of traits

In 1866, Gregor Mendel published the results of years of experimentation in breeding pea plants. He showed that both parents must pass discrete physical factors which transmit information about their traits to their offspring at conception. An individual inherits one such unit for a trait from each parent. Mendel's principle of dominance explained that most traits are not a blend of the fathers traits and those of the mother as was commonly thought. Instead, when an offspring inherits a factor for opposing forms of the same trait, the dominant form of that trait will be apparent in that individual. The factor for the recessive trait, while not apparent, is still part of the individuals genetic makeup and may be passed to offspring.

Mendels experiments demonstrated that when sex cells are formed, the factors for each trait that an individual inherits from its parents are separated into different sex cells. When the sex cells unite at conception the resulting offspring will have at least two factors (alleles) for each trait. One inherited factor from the mother and one from the father. Mendel used the laws of probability to demonstrate that when the sex cells are formed, it is a matter of chance as to which factor for a given trait is incorporated into a particular sperm or egg.

We now know that simple dominance does not explain all traits. In cases of co-dominance, both forms of the trait are equally expressed. Incomplete dominance results in a blending of traits. In cases of multiple alleles, there are more than just two possible ways a given gene can be expressed. We also now know that most expressed traits, such as the many variations in human skin color, are influenced by many genes all acting on the same apparent trait. In addition, each gene that acts on the trait may have multiple alleles. Environmental factors can also interact with genetic information to supply even more variation. Thus sexual reproduction is the biggest contributor to genetic variation among individuals of a species.

Twentieth-century scientists came to understand that combining the ideas of genetics and natural selection could lead to enormous strides in understanding the variety of organisms that inhabit our earth.

Mutation

Scientists realized that the molecular makeup of genes must include a way for genetic information to be copied efficiently. Each cell of a living organism requires instructions on how and when to build the proteins that are the basic building blocks of body structures and the workhorses responsible for every chemical reaction necessary for life. In 1958, when James Watson and Francis Crick described the structure of the DNA molecule, this chemical structure explained how cells use the information from the DNA stored in the cells nucleus to build proteins. Each time cells divide to form new cells, this vast chemical library must be copied so that the daughter cells have the information required to function. Inevitably, each time the DNA is copied, there are minute changes. Most such changes are caught and repaired immediately. However, if the alteration is not repaired the change may result in an altered protein. Altered proteins may not function normally. Genetic disorders are conditions that result when malfunctioning proteins adversely affect the organism. [Gallery: Images of DNA Structures]

In very rare cases the altered protein may function better than the original or result in a trait that confers a survival advantage. Such beneficial mutations are one source of genetic variation.

Gene flow

Another source of genetic variation is gene flow, the introduction of new alleles to a population. Commonly, this is due to simple migration. New individuals of the same species enter a population. Environmental conditions in their previous home may have favored different forms of traits, for example, lighter colored fur. Alleles for these traits would be different from the alleles present in the host population. When the newcomers interbreed with the host population, they introduce new forms of the genes responsible for traits. Favorable alleles may spread through the population. [Countdown: Genetics by the Numbers 10 Tantalizing Tales]

Genetic drift

Genetic drift is a change in allele frequency that is random rather than being driven by selection pressures. Remember from Mendel that alleles are sorted randomly into sex cells. It could just happen that both parents contribute the same allele for a given trait to all of their offspring. When the offspring reproduce they can only transmit the one form of the trait that they inherited from their parents. Genetic drift can cause large changes in a population in only a few generations especially if the population is very small. Genetic drift tends to reduce genetic variation in a population. In a population without genetic diversity there is a greater chance that environmental change may decimate the population or drive it to extinction.

Mary Bagley, LiveScience Contributor

Further reading:

Read more:
Genetics: The Study of Heredity | Live Science

Read More...

Darwin and Genetics | Genetics

April 24th, 2020 5:46 pm

Abstract

Darwin's theory of natural selection lacked an adequate account of inheritance, making it logically incomplete. We review the interaction between evolution and genetics, showing how, unlike Mendel, Darwin's lack of a model of the mechanism of inheritance left him unable to interpret his own data that showed Mendelian ratios, even though he shared with Mendel a more mathematical and probabilistic outlook than most biologists of his time. Darwin's own pangenesis model provided a mechanism for generating ample variability on which selection could act. It involved, however, the inheritance of characters acquired during an organism's life, which Darwin himself knew could not explain some evolutionary situations. Once the particulate basis of genetics was understood, it was seen to allow variation to be passed intact to new generations, and evolution could then be understood as a process of changes in the frequencies of stable variants. Evolutionary genetics subsequently developed as a central part of biology. Darwinian principles now play a greater role in biology than ever before, which we illustrate with some examples of studies of natural selection that use DNA sequence data and with some recent advances in answering questions first asked by Darwin.

The power of Selection, whether exercised by man or brought into play under nature through the struggle for existence and the consequent survival of the fittest, absolutely depends on the variability of organic beings. Without variability, nothing can be effected; slight individual differences, however, suffice for the work, and are probably the chief or sole means in the production of new species. Charles Darwin (1868)

CHARLES Darwin was the first person to appreciate clearly that evolution depends on the existence of heritable variability within a species to generate the differences between ancestral and descendant populations. The development of Darwin's thoughts on the nature and causes of evolution is clearly documented in his transmutation notebooks of 18361838 (Barrett et al. 1987). Once he had decided that species originated by descent with modification, Darwin quickly realized the need to find a mechanism for accomplishing the changes involved. In formulating the idea of natural selection, he was greatly influenced by the experience of breeders in artificially selecting populations of domestic animals and plants. Chapter 1 of The Origin of Species (Darwin 1859) is famously devoted to documenting the existence of variability in these populations and the effectiveness of artificial selection:

The key is man's power of cumulative selection: nature gives successive variations; man adds them up in certain directions useful to himself (Darwin 1859, p. 30).

It was only a short step to applying this observation to selection in nature:

Can it, then, be thought improbable, seeing that variations useful to man have undoubtedly occurred, that other variations useful in some way to each being in the great and complex battle of life, should sometimes occur in the course of thousands of generations? This preservation of favourable variations and the rejection of injurious variations, I call Natural Selection (Darwin 1859, pp. 8182).

Most of the books and papers that Darwin published after The Origin of Species were devoted to describing how a vast range of biological phenomenafrom the sexual systems of plants to human anatomy and behaviorcould be interpreted in terms of evolution by natural selection or by the special form of natural selection represented by sexual selection. Surprisingly (at least from today's perspective), many biologists were, for a long time, far from convinced that natural selection was the predominant guiding force in evolution. This continued into the 1920s. In the Introduction to Volume 1 of his treatise on evolutionary genetics, Sewall Wright noted:

Along with the universal acceptance by biologists of evolution as a fact, there came to be increasing dissatisfaction, during the latter part of the nineteenth century, with natural selection as the master theory of causation (Wright 1968, pp.78).

Prominent early geneticists such as William Bateson, Hugo de Vries, and Richard Goldschmidt were notorious skeptics about natural selection and the evolutionary role of the small individual differences relied on by Darwin, emphasizing instead the role of mutations with large and manifold effects (Provine 1971). Many naturalists and paleontologists held what now seem to us to be semi-mystical theories, such as internal drives to improvement or perfection; many of them espoused Lamarckian views up until the 1930s (in France and in the Soviet Union and its satellites, Lamarckism persisted well into the 1960s). In his classic history of modern science, The Edge of Objectivity, Charles Coulston Gillispie quotes the leading historian of biology in 1929, Erik Nordenskiold, as stating that the proposition that natural selection does not operate in the form imagined by Darwin must certainly be taken as proved (Gillispie 1960, p. 320). The book Evolution in the Light of Modern Knowledge, a compendium of essays by 13 leading British biologists, published by Blackie and Son in 1925 to provide (according to the publisher's note) an authoritative statement about the doctrine of evolution...after the general upheaval of fundamental theories in the past 20 years, has no index reference to natural selection. This contrasts with 3253 articles mentioning natural selection and evolution in 2008 in the Web of Science database. For a detailed discussion of anti-Darwinian evolutionary ideas, see Bowler (1983) and Gayon (1998).

Why was there such skepticism toward natural selection, and why have things changed so much? One reason was the lack during Darwin's lifetime of direct evidence for natural selection. This started to change in the late 19th and early 20th centuries through the work of Bumpus (1899) in the United States, and Weldon (1895, 1901) and his student Di Cesnola (1907) in Europe. These scientists initiated the field now known as ecological genetics, and we now have literally thousands of examples where field naturalists have demonstrated the operation of natural selection in the wild on both discrete polymorphisms and quantitative traits (Kingsolver et al. 2001; Bell 2008; Leimu and Fischer 2008).

The other major factor, of course, was the fact that Darwin failed to arrive at an understanding of the mechanism of inheritance, despite realizing its importance and devoting a vast effort to assembling evidence in his Variation of Animals and Plants Under Domestication (Darwin 1868). Unfortunately, he was unaware of Mendel's work, despite its publication 2 years earlier (Mendel 1866). Mendel's work has now, of course, permanently revolutionized our understanding of heredity, and his tragic failure to obtain recognition in his lifetime is a well-known story. It is less well known that Mendel was well aware of the importance for evolution of understanding genetics:

This seems to be the one correct way of finally reaching a solution to a question whose significance for the evolutionary history of organic forms cannot be underestimated (Mendel 1866, p. 2).

Sadly, even if Mendel had lived to see the rediscovery of his work, he probably would not have had the satisfaction of seeing it contribute to evolutionary understanding because, even after genetics had begun its rapid development in the early decades of the 20th century, evolutionary biologists initially failed to understand how to incorporate genetics into their work. We will outline these failures to achieve a synthesis later, but first consider Darwin's efforts to understand inheritance and how his approach fell short of Mendel's.

Mendel's ability to solve the most difficult problem in 19th century biology after the mechanism of evolution rests on his use of a then-unique approach: combining rigorous genetic experiments with quantitative, probabilistic predictions about their expected outcomes: in other words, using biological data to test a quantitative hypothesis. It is a triumph of productive theoretical reasoning that Mendel proposed his particulate inheritance hypothesis well before a proper understanding of the cellular basis of sexual reproduction was achieved by either animal or plant biologists (Farley 1982).

This achievement eluded Darwin, the other greatest mind in 19th century biology, although he came close to seeing the same phenomena as Mendel did and frequently looked at data in a quantitative manner (Howard 2009). Darwin repeatedly referred to the phenomenon of reversion to ancestral types in Variation of Animals and Plants Under Domestication (Darwin 1868). He also compiled examples of the transmission of traits down several generations of pedigrees and obtained help from the mathematical physicist Sir George Stokes to show that these cases are unlikely to be due to chance, one of the first examples of a test of statistical significance in biology (Darwin 1868, chap. 12).

Ironically, Darwin analyzed data from his own crossing experiments on distyly in Primula species (summarized in Darwin 1877, chap. 5), which gave what we can now see as clear evidence for Mendelian ratios (see also Bulmer 2003, p.112, and Howard 2009). In distylous species (Figure 1), the long-styled morphs (L) are now known to be homozygotes ss for the alleles at several loci in a supergene controlling style length, stamen position, pollen and stigma placement, morphology, and incompatibility, whereas the short-styled morph (S) is heterozygous Ss. The only matings that invariably succeed are L S and S L (Darwin called these legitimate pollinations), and these give a 1:1 ratio of L and S plants (Table 1). It is occasionally possible to obtain seeds by self-fertilization, in which case L plants produce only L offspring (Table 1). Darwin stated:

Distyly in primroses. (A) Long-styled (pin) and short-styled (thrum) flowers of Primula vulgaris. (B) Vertically sectioned flowers, with the compatible pollinations indicated. (Pollen from high anthers is compatible with stigmas of long-styled plants, and pollen from low anthers is compatible with stigmas of short-styled plants, while the other two types of pollinations are incompatible.)

Darwin's results for progeny of long- and short-styled Primula crossed with the same morph

From the long-styled form, always fertilised with its own-form pollen, I raised in the first generation three long-styled plants, from their seed 53 long-styled grandchildren, from their seed 4 long-styled great-grandchildren, from their seed 20 long-styled great-great-grandchildren, and lastly, from their seed 8 long-styled and 2 short-styled great-great-great-grandchildren. altogether 162 plants were raised, 156 long-styled and 6 short-styled (Darwin 1877, pp. 228229).

The few short-styled plants in the final generation were presumably contaminants (Darwin's experiments were remarkably free from them). Self-pollination of S plants should generate a 3:1 ratio, as Darwin found (see Table 1; none of the ratios deviates significantly from the expected ratio). He remarked:

I raised at first from a short-styled [P. sinensis] plant fertilised with its own-form pollen one long-styled and seven short-styled illegitimate seedlings . Dr. Hildebrand raised fourteen plants, of which eleven were short-styled and three long-styled (Darwin 1877, p. 216).

Darwin failed to understand the significance of these results because he had no model of particulate inheritance that could be applied to genetic data. Indeed, Darwin appears to have maintained a belief in the predominance of blending inheritance, as did nearly all of his contemporaries. As Fisher pointed out in chapter 1 of The Genetical Theory of Natural Selection (Fisher 1930), there are few explicit statements on this in Darwin's published works, although they appear in some of his unpublished notes and essays. In addition, chapter 15 of Variation of Animals and Plants Under Domestication (Darwin 1868) starts with a section On Crossing as a Cause of Uniformity of Character, which implicitly assumes that crossing leads to blending. It is unclear, however, to what extent he thought that an offspring was a product of the complete fusion of the genetic contributions of its parents (Bulmer 2003, chap. 4).

Blending inheritance leads to a difficulty that was forcefully pointed out by Fleeming Jenkin (Jenkin 1867), the professor of engineering at the University of Edinburgh (the building next to ours is, somewhat unfortunately perhaps, named after him). Under blending inheritance, variation decays rapidly because the genotypes of the offspring of a cross are all the same and are intermediate between those of the two parents. With random mating, the genetic variance of a quantitative trait then decays by a factor of one-half each generation (Fisher 1930, p. 4). Acceptance of blending inheritance clearly raises doubts about the ability of either natural or artificial selection to make permanent changes in a population. In the sixth edition of The Origin of Species, published in 1872, Darwin reacted to Jenkin as follows:

Nevertheless, until reading an able and valuable article in the North British Review (1867), I did not appreciate how rarely single variations, whether slight or strongly-marked, could be perpetuated (Darwin 1859, pp. 111112).

Since heritable variability is required for selection to be effective, and Darwin's survey of the results of artificial selection had convinced him that there is enough variation for it to be effective, Darwin sought a way of generating an abundance of such variation. This was provided by his theory of pangenesis, according to which variations experienced by the individual during its lifetime are transmitted to the germ cells by hypothetical gemmules (Darwin 1868, chap. 27). This is an hypothesis of the inheritance of acquired characters, which Darwin accepted as an experimentally established fact (there is an extensive discussion on the transmission of mutilations in Darwin 1868, chap. 12).

However, Darwin was clearly not quite sure about this. For example, he mentioned that the circumcision of male infants has not led to a loss of the foreskin in the Jewish community (Darwin 1868, Vol. 1, p. 558). He also noted that there are some instances of evolution that cannot be explained by this hypothesis, notably the adaptive characteristics of the sterile castes of social insects:

For no amount of exercise, or habit, or volition, in the utterly sterile members of a community could possibly have affected the structure or instincts of the fertile members, which alone leave descendants. I am surprised that no one has advanced this demonstrative case of neuter insects, against the well-known doctrine of Lamarck (Darwin 1859, p. 242).

Darwin's use of this natural case of sib selection to refute Lamarckism anticipates later uses of the same reasoning, which reached a peak of perfection in the Lederbergs' experiments on replica plating in Escherichia coli (Lederberg and Lederberg 1952).

Unlike Darwin, who regarded the inheritance of acquired characters largely as a source of variation on which selection could act, the 20th century advocates of Lamarckian inheritance viewed it as an alternative explanation of adaptive evolution. As was brilliantly laid out by Fisher in chapter 1 of The Genetical Theory of Natural Selection, and as is no doubt familiar to readers of Genetics, all the difficulties posed by blending disappear with Mendelian inheritance: variability within a population is conserved, not lost, when no evolutionary forces are acting, a genetic equivalent to Galileo's law of inertia. The inheritance of acquired characters is therefore not needed for the regeneration of genetic variability.

It is, of course, well known that our knowledge of the physical basis of genes and of their behavior now largely excludes Lamarckian inheritance. However, recent studies have uncovered some situations in which the DNA of certain genome regions is modified during the life of an individual, and these epigenetic marks with functions in developmental control and other processes can sometimes pass via meiotic divisions to descendant generations (e.g., Cubas et al. 1999; Richards 2006; Namekawa et al. 2007; Heijmans et al. 2008; Sidorenko and Chandler 2008). If variants that arise in this way are stably transmitted, then they can be treated as Mendelian variants that can be exploited in evolution. If their inheritance is unstable, as is often the case, they cannot contribute significantly to evolution.

The breakthrough in understanding the nature of variation in quantitative traits (equivalent to Darwin's slight differences, which may be called individual differences; see the epigraph to this article) came in the early years of genetics, starting with experiments with pure lines, whose individuals have virtually identical genotypes. These experiments showed that plentiful phenotypic variation exists among such individuals but is not transmissible to the offspring (Johannsen 1909; Wright 1920), leading to the rejection of Lamarckian inheritance by the genetics community. Furthermore, the variability of quantitative traits (which often show apparent blending in F1 crosses between pure lines) increases in F2 and later generations (Nilsson-Ehle 1909; East 1910), as expected with particulate Mendelian inheritance. Moreover, the factors responsible can be mapped to chromosomal regions and sometimes (with modern methods) to single genes or nucleotide variants (Flint and Mackay 2009). Even initially puzzling cases of very complex patterns of inheritance, such as beaded and truncate wing in Drosophila, were traced to factors linked to chromosomal genes, and the virtual universality of Mendelism was established by the early 1920s (Altenburg and Muller 1920). In contrast to the inheritance of acquired characters, mutations were found to be very rare, stable modifications of genes and to arise independently of whether or not they confer increased fitness in a given environment (Muller 1932).

By the 1920s, it was clear that (contrary to the beliefs of many early geneticists, who emphasized the large effects of dramatic mutations and ignored the evidence for the Mendelian basis of quantitative trait variation), Darwinian evolution by natural selection is, in fact, enabled by Mendelian inheritance: mutations in genes provide the source of new, stable variants on which selection can act. This set the stage for understanding that evolution is fundamentally a process of change in the frequencies of Mendelian variants within populations and species, leading to the development of classical population and quantitative genetics. The fascinating struggle to reach this understanding is ably described by Provine (1971).

The chief post-Darwin component of major importance in modern evolutionary thinking is the idea of genetic drift and, specifically, the possibility that a significant portion of variability and evolution of DNA sequence variants is driven by random fluctuations in the frequencies of variants with little or no effects on fitness (Kimura 1983). Darwin himself had the idea of selective neutrality:

Variations neither useful nor injurious would not be affected by natural selection, and would be left a fluctuating element, as perhaps we see in the species called polymorphic (Darwin 1859, p. 81).

In a surprising turn of events, the concept of selective neutrality has become a cornerstone of modern tests for natural selection, by providing a null hypothesis that can be tested against data on sequence variation and evolution. Evolutionary biology is now mature enough to repay its debt to genetics and indeed is now (together with genetic and molecular genetic approaches) central to work initiated with largely functional genetic motivations, including genome sequencing.

Given some genetic variation in a phenotype of interest, ecological genetic approaches can relate fitnesses to the differences between individuals within a single natural population, sometimes using data on undisturbed individuals (Bell 2008). With more disturbance to the organisms, between-population differences can also be tested for their selective importance by using methods such as reciprocal transplant experiments. Changes in genotype frequencies can be followed over time in such experiments or after perturbing alleles from their natural frequencies. These approaches have firmly documented the action of selection, sometimes on unexpected characters such as the inversion polymorphisms of Drosophila (Wright and Dobzhansky 1946). However, this approach may miss many instances of selection, because even the largest and most sensitive experiments, such as those involving competition between strains of yeast or bacteria, cannot detect selective differences <0.1% in magnitude (Dykhuizen 1990).

At the other extreme of the evolutionary timescale, the comparative approach can be used to relate differences in ecological conditions experienced by different evolving lineages to differences in the outcome of evolution by natural selection (Harvey and Pagel 1991). Darwin was the first biologist to explicitly use the comparative approach for this purpose. This approach is now highly statistical (Felsenstein 2004) and often uses sequence-based phylogenies, which have the advantage of being much less susceptible to the action of natural selection in causing variation in the rate and direction of character change than the morphological traits formerly used in phylogenetic analysis. Even without modern methods, Darwin used the comparative method to good effect in his work on plant mating system evolution, for example, in his review of the literature to show that inbreeding plants have smaller flowers and are generally less attractive to pollinators compared with outcrossing ones (Darwin 1876), a finding that has held up in more comprehensive modern studies and that tells us that attracting pollinators consumes resources (e.g., Ornduff 1969). The comparative approach is, however, incapable of providing estimates of the intensity of selection involved in causing the changes observed.

Modern DNA sequencing technology provides population geneticists with the ability to study the extent to which selection acts on variants across the genome, as opposed to mutation and random genetic drift. After several decades of using the ecological genetic and comparative approaches to detect selection in nature on visible or physiological traits, biologists can now test for the selective effects of specific genetic differences between individuals without needing to know their phenotypic effects. For these tests, neutrality provides an essential null hypothesis. With our newly acquired ability to apply statistical population genetics methods to the analysis of patterns of within-species variation and between-species divergence in large, genomewide data sets, extremely weak pressures of selection, well below the resolution of experimental methods, can be detected and measured. Many of the approaches currently being used are closely based on the classical work of Fisher, Kimura, and Wright on the behavior of variants subject to mutation, selection, and genetic drift, which are summarized in Kimura's (1983) book, The Neutral Theory of Molecular Evolution. These methods are often extremely computationally intensive, especially when complications like recent changes in population size are taken into account.

With the increasing availability of large data sets on DNA sequence variation across the genomes of humans and Drosophila melanogaster, we are getting close to answering questions such as: What is the distribution of selection coefficients for newly arising deleterious amino acid mutations? What fraction of amino acid variants distinguishing related species are fixed by natural selection, as opposed to genetic drift acting on neutral or slightly deleterious variants? To what extent are variants at synonymous coding sites and noncoding sites subject to selection, and how strong is this selection?

The results are sometimes quite startling. It has been fairly conclusively established, for example, that a typical human being is heterozygous for several hundred amino acid mutations, most of which have only very small effects on fitness (of the order of 103) (Boyko et al. 2008), that 50% of amino acid variants distinguishing related Drosophila species have been fixed by selection (Sella et al. 2009), and that more noncoding sites than coding sites in both humans and Drosophila can mutate to selectively deleterious alternatives that are rapidly removed by selection (Encode Project Consortium 2007; Haag-Liautard et al. 2007).

In addition to these direct tests of selection on variants, we can also use information on neutral or nearly neutral variants that are not themselves under selection to make inferences about selection at linked sites in the genome. One example is the detection of selective sweeps caused by the recent spread of selectively favorable mutations. The spread of an advantageous allele can quickly lead to very low variability in the gene affected, and closely linked regions may also have reduced diversity as a result of hitchhiking through the population of the segment of the chromosome that contained the original beneficial mutation (Maynard Smith and Haigh 1974). These effects on linked neutral or nearly neutral variants can be used in statistical tests for the action of natural selection. This has enabled geneticists to detect and estimate the strength of selection acting on genes such as drug resistance genes in the human malaria parasite by using the variability of microsatellite markers (e.g., Nash et al. 2005) to detect numerous examples of recent adaptations in human populations from their effects on patterns of variation at linked SNPs (e.g., Currat et al. 2002; Sabeti et al. 2002; Williamson et al. 2007; Akey 2009) and to search for genes involved in responses to artificial selection (Walsh 2008).

Conversely, high variability in a region can betray the action of natural selection acting in such a way that different alleles are maintained as polymorphisms for a long period by balancing selection; this divides the population into two or more compartments, between which neutral differences can accumulate at sites that are closely linked to the targets of selection, where recombination is ineffective at preventing differentiation between the compartments (Hudson 1990; Nordborg 1997). A well-known example is the human MHC region, in which not only are there many polymorphic amino acids in exon 2, which encodes most of the peptide-binding residues of the human mature MHC proteins, but after there are extraordinarily numerous polymorphic variants of synonymous and intron sites, compared with other loci in the same populations (Raymond et al. 2005). Similarly, frequency-dependent selection has clearly maintained sequence polymorphism for long evolutionary times at plant and fungal self-incompatibility loci, whose sequences are highly diverged (e.g., Vekemans and Slatkin 1994; Richman et al. 1996; May et al. 1999).

Not only can selection within single populations be studied by molecular evolutionary approaches, but between-population differences due to local adaptation can also be revealed by increased divergence at sites linked to the targets of selection (Beaumont and Balding 2004). Indeed, scans of human and other species' genomes for sequences that are more differentiated than most genes are a major way of discovering candidates for genes that are currently under selection (Akey 2009).

Another way in which modern evolutionary studies have contributed to genetics, as opposed to genetics contributing to evolutionary biology, is that an interest in quantifying the extent of genetic variation [initially motivated by a debate about whether variation within species is largely composed of recent mutations or includes a considerable proportion of variants maintained by balancing selection (Dobzhansky 1955; Lewontin 1974)] ultimately led to the discovery of vast numbers of DNA sequence variants that can be used as genetic markers for mapping (although these data did not in themselves settle the debate about whether selection maintains variation). The existence of abundant markers was predicted long ago:

It would accordingly be desirable, in the case of man, to make an extensive and thorough-going search for as many factors as possible that could be usedas identifiers. They should, preferably, involve character differences that are (1) of common occurrence, (2) identifiable with certainty, (3) heritable in a simple Mendelian fashion. It seems reasonable to suppose that in a species so heterozygous there must really be innumerable such factors present. It does seem clear that in the more tractable organisms, such as the domesticated and laboratory races of animals and plants, character analysis by means of linkage studies with identifying factors will come into more general use (Altenburg and Muller 1920).

In some species, naturally occurring markers can now be obtained so densely that new approaches are needed for genetic mapping because there is a very low chance of a crossover event between the closest markers (e.g., Churchill et al. 2004; Van Os et al. 2005; Flibotte et al. 2009). The possibility of obtaining large numbers of genetic markers has produced renewed progress in mapping genes affecting quantitative characters, and new approaches are being developed for such studies, including association mapping that makes use of the population genetics concept of linkage disequilibrium (associations between the allelic states of different loci or sites in a sequence; see Slatkin 2008 for an overview). The study of the population genetics of multi-locus systems once appeared to be an esoteric field, remote from empirical data, which contributed to the reputation of theoretical population genetics for dryness and irrelevance to biology. Nevertheless, very important principles were developed that are now widely used by other geneticists, including ways to measure linkage disequilibrium [also now used to estimate recombination rates in genomes by using samples of sequences from populations (Myers et al. 2005)] and the concept that selection acting on a given sequence variant or allele has effects on closely linked variants (see above).

The kinds of approaches just mentioned are no longer restricted to humans and the genetics model organisms of most interest for functional molecular genetic work. One well-established use of markers is to infer the mating systems of populations in the wild (Ritland 1990). Darwin anticipated this when he used phenotypic differences, including flower colors, that he clearly assumed to be inherited, to infer the parentage of seeds:

Altogether 233 plants were raised, of which 155 were mongrelised in the plainest manner, and of the remaining 78 not half were absolutely pure. I repeated the experiment by planting near together two varieties of cabbage with purple-green and white-green lacinated leaves; and of the 325 seedlings raised from the purple-green variety, 165 had white-green and 160 purple-green leaves. Of the 466 seedlings raised from the white-green variety, 220 had purple-green and 246 white-green leaves. These cases show how largely pollen from a neighbouring variety of the cabbage effaces the action of the plant's own pollen (Darwin 1876, p. 393).

It is now becoming possible to conduct fine-scale genetic mapping studies in nonmodel species, including those of applied interest, such as domesticated animals and plants and their pathogens, where QTL mapping is being aided by the abundant supply of new markers. Genetic mapping gives promise of testing hypotheses such as the close linkage of genes involved in heterostyly in Primula and other plant species (Li et al. 2007; Labonne et al. 2009) and mimicry in butterflies (Baxter et al. 2008), examples of problems that interested Darwin. Gene mapping is also important in modern work on the genetics of speciation, which is at last identifying genes involved in reproductive isolation between closely related species and is uncovering evidence for the DobzhankyMuller hypothesis that natural selection is important in causing genetic differences between populations that lower the survival or fertility of F1 or F2 hybrids, as a result of deleterious epistatic interactions between alleles derived from the two populations (e.g., Barbash et al. 2003; Presgraves et al. 2003). As is well known, Darwin himself found the evolution of reproductive isolation puzzling:

The importance of the fact that hybrids are very generally sterile, has, I think, been much underrated by some late writers. On the theory of natural selection the case is especially important as the sterility of hybrids could not possibly be of any advantage to them, and therefore could not have been acquired by the continued preservation of successive profitable degrees of sterility (Darwin 1859, p. 245).

However, the title The Origin of Species did not refer to this central puzzle concerning speciation, but rather to the evolution of adaptations and character differences; before the rise of genetics, it would have been virtually impossible for a correct interpretation of reproductive isolation to have been developed.

Another long-debated topic for which genetic marker availability should help our understanding is the question of the genetic basis of inbreeding depression and of heterosis. Although the deleterious effects of inbreeding were known to some earlier biologists, Darwin was the first to study the phenomenon thoroughly, because he realized that it provides an explanation for the existence of the elaborate adaptations of plants to avoid inbreeding. Darwin's book The Effects of Cross and Self Fertilization in the Vegetable Kingdom described his own experiments comparing progeny produced by self- and cross-fertilization in 57 plant species, and his summary of the main results anticipated future work that allowed us to measure inbreeding (in modern terms, inbreeding coefficients):

That certain plants, for instance, Viola tricolor, Digitalis purpurea, Sarothamnus scoparius, Cyclamen persicum, etc., which have been naturally cross-fertilised for many or all previous generations, should suffer to an extreme degree from a single act of self-fertilisation is a most surprising fact. Nothing of the kind has been observed in our domestic animals; but then we must remember that the closest possible interbreeding with such animals, that is, between brothers and sisters, cannot be considered as nearly so close a union as that between the pollen and ovules of the same flower. Whether the evil from self-fertilisation goes on increasing during successive generations is not as yet known; but we may infer from my experiments that the increase if any is far from rapid. After plants have been propagated by self-fertilisation for several generations, a single cross with a fresh stock restores their pristine vigour; and we have a strictly analogous result with our domestic animals (Darwin 1876, p. 438).

As pointed out by Fisher in his Design of Experiments (Fisher 1935, chap. 3), Darwin used paired contrasts of the performance of an inbred and an outbred plant grown in the same pot, a method that is widely used in modern biological statistics. Darwin's insight into the utility of this approach was spoiled by the reanalysis of his data conducted by his cousin, Francis Galton, a supposedly more expert statistician.

Just as with his theory of sexual selection to explain male/female dimorphism (Darwin 1871), which was largely neglected until the 1970s, the individual selective advantage to outcrossing arising from inbreeding depression postulated by Darwin was rejected by leading 20th century thinkers on plant evolution, such as C. D. Darlington and G. L. Stebbins, in favor of group selection hypotheses of advantages of increased variability to the population or species. The role of inbreeding depression in the evolution of mating systems is, however, now well established (Barrett 2002).

Although Darwin was unable to provide a satisfactory interpretation of his observations, inbreeding depression is now well known to be a genetic phenomenon, and hybrid vigor (heterosis) is widely used in agriculture. It is also well known that the genetic basis of these phenomena is difficult to ascertain and that this may impede efforts to make the best use of heterosis. There is no doubt that rare, deleterious mutations play an important role (Charlesworth and Charlesworth 1999): inbreeding, by producing homozygotes for such mutations, reduces survival and fertility because a large proportion of deleterious mutations are recessive, or partially so, and cause only slight harm when heterozygous, as was first clearly proposed by D. F. Jones (Jones 1917). Heterosis is also explicable on this basis because different inbred strains will be homozygous for different deleterious mutations, and different populations of a species in nature will differ similarly at some proportion of their genes, particularly if the populations are highly isolated (Ingvarsson et al. 2000; Escobar et al. 2008). It is still much less clear whether loci with overdominant alleles (alleles showing heterozygote advantage) also contribute any major part of inbreeding depression or heterosis, although it is intuitively easy to understand that, if such loci are common, these effects would be produced. Identification of the genetic factors involved in inbreeding depression or heterosis by the fine-scale mapping methods referred to above should help to answer these questions.

The examples that we have outlined here show the value of the ongoing interaction between genetics and the study of evolution. From being a major headache for early supporters of evolution, genetics paved the way for models of evolution based on the known properties of inheritance, so that the constraints experienced by genes and genomes in evolution were correctly incorporated into quantitative models, and new possibilities, unknown to Darwin, were discovered.

Evolutionary genetics is inherently interdisciplinary, fruitfully combining models (often mathematical and often stochastic, given the nature of genetics) with empirical data. This intellectual tradition, now 100 years old, deserves celebration along with Darwin's anniversaries. We hope that we have shown that evolution is more central to modern biological research than ever before and that this productive collaboration with genetics can be predicted to yield many further pure and applied scientific riches in the next hundred years. For this to happen, the need for a broad-enough education must be met. Biologists and doctors will need to understand genetics, and even some population genetics concepts, at least enough to collaborate with people with expertise in relevant quantitative methods. Mathematical ideas need to be demystified, as far as possible, so that biologists using phylogenetic and genetic marker or diversity analyses know what lies behind the computer programs that they use, an understanding without which the numbers that come out may lead to wrong conclusions. We need to regain a respect for the usefulness of statistics throughout biology and use it to test our ideas, as Darwin started to do. The same applies to theoretical modeling directed toward testable hypotheses, of which the idea of natural selection is still an excellent example, even though it has been extended to a far wider realm of biology than Darwin initially proposed and has given us many valuable tools at the interface between genetics and evolution. Darwin himself was interested in the functioning of organisms, not just in their morphology and relationships and the history of life, and he would surely have been delighted to see where his ideas have so far led us and how they have continued to be central within biology. In Dobzhansky's famous words:

Nothing in biology makes sense except in the light of evolution (Dobzhansky 1973).

We thank Adam Wilkins and two reviewers for their helpful suggestions for improving the manuscript.

Akey, J. M., 2009 Constructing genomic maps of positive selection in humans: Where do we go from here? Genome Res. 19: 711722.

Altenburg, E., and H. J. Muller, 1920 The genetic basis of truncate wing: an inconstant and modifiable character in Drosophila. Genetics 5: 159.

Barbash, D. A., D. F. Siino, A. M. Tarone and J. Roote, 2003 A rapidly evolving MYB-related protein causes species isolation in Drosophila. Proc. Natl. Acad. Sci. USA 6: 53025307.

Barrett, P. H., P. J. Gautrey, S. Herber, D. Kohn and S. Smith, 1987 Charles Darwin's Notebooks, 18361844. Cornell University Press, Ithaca, NY.

Barrett, S. C. H., 2002 The evolution of plant sexual diversity. Nat. Rev. Genet. 3: 274284.

Baxter, S., R. Papa, N. Chamberlain, S. Humphray, M. Joron et al., 2008 Convergent evolution in the genetic basis of Muellerian mimicry in Heliconius butterflies. Genetics 180: 15671577.

Beaumont, M. A., and D. J. Balding, 2004 Identifying adaptive genetic divergence among populations from genome scans. Mol. Ecol. 13: 969980.

Bell, G., 2008 Selection, Ed. 2. Oxford University Press, Oxford.

Bowler, P. J., 1983 Eclipse of Darwinism: Anti-Darwinian Evolution Theories in the Decade Around 1900. Johns Hopkins University Press, Baltimore.

Boyko, A., S. H. Williamson, A. R. Indap, J. D. Degenhardt, R. D. Hernandez, et al., 2008 Assessing the evolutionary impact of amino-acid mutations in the human genome. PLOS Genet. 5: e1000083.

Bulmer, M. G., 2003 Francis Galton. Johns Hopkins University Press, Baltimore.

Bumpus, H. C., 1899 The elimination of the unfit as illustrated by the introduced sparrow, Passer domesticus. Biol. Lectures Woods Hole Marine Biol. Station 6: 209226.

Charlesworth, B., and D. Charlesworth, 1999 The genetic basis of inbreeding depression. Genet. Res. 74: 329340.

Churchill, G. A., D. C. Airey, H. Allayee, J. M. Angel, A. D. Attie et al., 2004 The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36: 11331137.

Cubas, P., C. Vincent and E. S. Coen, 1999 An epigenetic mutation responsible for natural variation in floral asymmetry. Nature 401: 157161.

Currat, M., G. Trabuchet, D. Rees, P. Perrin, R. M. Harding et al., 2002 Molecular analysis of the beta-globin gene cluster in the Niokholo Mandenka population reveals a recent origin of the beta(S) Senegal mutation. Am. J. Hum. Genet. 70: 207223.

Darwin, C. R., 1859 The Origin of Species. John Murray, London.

Darwin, C. R., 1868 Variation of Animals and Plants Under Domestication. John Murray, London.

Darwin, C. R., 1871 The Descent of Man and Selection in Relation to Sex. John Murray, London.

Darwin, C. R., 1876 The Effects of Cross and Self Fertilization in the Vegetable Kingdom. John Murray, London.

Darwin, C. R., 1877 The Different Forms of Flowers on Plants of the Same Species. John Murray, London.

Di Cesnola, A. P., 1907 A first study of natural selection in Helix arbustorum (Helicogena). Biometrika 5: 387399.

Dobzhansky, T., 1955 A review of some fundamental concepts and problems of population genetics. Cold Spring Harbor Symp. Quant. Biol. 20: 115.

Dobzhansky, T., 1973 Nothing in biology makes sense except in the light of evolution. Am. Biol. Teach. 35: 125129.

Dykhuizen, D. E., 1990 Experimental studies of natural selection in bacteria. Annu. Rev. Ecol. Evol. Syst. 21: 373398.

East, E. M., 1910 A Mendelian interpretation of variation that is apparently continuous. Am. Nat. 44: 6582.

Encode Project Consortium, 2007 Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799816.

Escobar, J., A. Nicot and P. David, 2008 The different sources of variation in inbreeding depression, heterosis and outbreeding depression in a metapopulation of Physa acuta. Genetics 180: 15931608.

Farley, J., 1982 Gametes and Spores. Johns Hopkins Press, Baltimore.

Felsenstein, J., 2004 Inferring Phylogenies. Sinauer, Sunderland, MA.

Fisher, R. A., 1930 The Genetical Theory of Natural Selection. Clarendon Press, Oxford.

Fisher, R. A., 1935 The Design of Experiments. Oliver & Boyd, Edinburgh.

Flibotte, S., M. Edgley, J. Maydan, J. Taylor, R. Zapf et al., 2009 Rapid high resolution single nucleotide polymorphism-comparative genome hybridization mapping in Caenorhabditis elegans. Genetics 181: 3337.

Flint, J., and T. F. C. Mackay, 2009 Genetic architecture of quantitative traits in mice, flies, and humans. Genome Res. 19: 723733.

Gayon, J., 1998 Darwinism's Struggle for Survival: Heredity and the Hypothesis of Natural Selection. Cambridge University Press, Cambridge, UK.

Gillispie, C. C., 1960 The Edge of Objectivity. Princeton University Press, Princeton, NJ.

Haag-Liautard, C., M. Dorris, X. Maside, S. Macaskill, D. L. Halligan et al., 2007 Direct estimation of per nucleotide and genomic deleterious mutation rates in Drosophila. Nature 445: 8285.

Harvey, P. H., and M. Pagel, 1991 The Comparative Method in Evolutionary Biology. Oxford University Press, Oxford.

Heijmans, B. T., E. W. Tobi, A. D. Stein, H. Putter, G. J. Blauw et al., 2008 Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl. Acad. Sci. USA 6: 1704617049.

Link:
Darwin and Genetics | Genetics

Read More...

On National DNA Day, scientists are trying to take the colonialism out of genetics – Massive Science

April 24th, 2020 5:46 pm

Scientists are trying to tackle the lack of diversity seen in genomics research, but even ambitious efforts, like the NIHs All of Us program, often fall short, especially when it comes to the inclusion of Indigenous communities. This is one of the reasons why the Decolonize DNA Day conference is taking place on April 24th, one day before the National DNA Day.

Traditionally, National DNA Day is an annual celebration of the discovery of DNA's double helix structure (1953) and the completion of the Human Genome Project (2003).

I was having conversations with colleagues on what would it mean to decolonize DNA, says Krystal Tsosie, an Indigenous (Din/Navajo) PhD student at Vanderbilt University. As an Indigenous academic, we always talk about what it means to Indigenize and re-Indigenize different disciplines of academia that have been historically more white-centred or white-dominated... and what it would mean to remove the colonial lens.

In collaboration with Latrice Landry and Jerome de Groot, Tsosie co-organized the Decolonize DNA Day Twitter conference to help re-frame narratives around DNA. Each speaker will have an hour to tweet out their "talk" and lead conversations on various topics, including how DNA ancestry testing fuels anti-Indigeneity and how to utilize emerging technologies to decolonize precision medicine.

There is a divide between people who are doing the science or the academic work, and the people who we want to inform, says Tsosie. Twitter is a great way to bridge that divide.

The Decolonize DNA Day conference is simply one effort to Indigenize genomics. Tsosie is also a co-founder of the Native BioData Consortium, a non-profit organization consisting of researchers and Indigenous members of tribal communities, focused on increasing the understanding of Native American genomic issues.

We dont really see a heavy amount of Indigenous engagement in genetic studies, which then means that as precision medicine advances as a whole [] those innovations are not going to be applied to Indigenous people, says Tsosie. How do we get more Indigenous people engaged?

Some of the answers can be found in a recent Nature Reviews Genetics perspective, penned by Indigenous scientists and communities, including those from the Native BioData Consortium. The piece highlights the actions that genomics researchers can take to address issues of trust, accountability, and equity. Recommended actions include the need for early consultations, developing benefit-sharing agreements, and appropriately crediting community support in any academic publications.

By switching power dynamics, were hoping to get genomic researchers to work with us, instead of against us, says Tsosie.

Read more:
On National DNA Day, scientists are trying to take the colonialism out of genetics - Massive Science

Read More...

Genetic variants linked with onset, progression of POAG – Modern Retina

April 24th, 2020 5:46 pm

Genetic variants that are unrelated to the IOP are associated with a family history of glaucoma and play a role in the onset of primary open-angle glaucoma (POAG). Genetic variants that are related to the IOP are associated with the age at which glaucoma is diagnosed and are associated with disease progression.

What is known about POAG, the most prevalent form of glaucoma, is that increased IOP and myopia are risk factors for damage to the optic nerve in POAG.

Related: Stent offers IOP stability more than three years after surgery

A family history of glaucoma is a major risk factor for development of POAG, in light of which, therefore, genetic factors are thought to be important in the disease pathogenesis and a few genes mutations have been identified as causing POAG, according to Fumihiko Mabuchi, MD, PhD, professor, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Kofu, Japan.

Myopia has been shown to be a risk factor for POAG in several studies. However, it can be difficult to diagnose true POAG in myopic patients and controversy exists over whether it is real risk factor.

Myopic optic discs are notoriously difficult to assess, and myopic patients may have visual field defects unrelated to any glaucomatous process.

The prevalence of POAG increases with age, even after compensating for the association between age and IOP.

Related: Preservative-free tafluprost/timolol lowers IOP well, glaucoma study shows

Part of the storyDr. Mabuchi and his and colleagues, recounted that these factors are only part of the story.

According to Dr. Mabuchi and his colleagues, cases of POAG caused by these gene mutations account for several percent of all POAG cases, and most POAG is presumed to be a polygenic disease.

Recent genetic analyses, the investigators explained, have reported genetic variants that predispose patients to development of POAG and the additive effect of these variants on POAG, which are classified as two types.

The first genetics variants are associated with IOP elevation.

Related: Sustained-release implant offers long-term IOP control, preserved visual function

View post:
Genetic variants linked with onset, progression of POAG - Modern Retina

Read More...

Meghan Trainor shows her work in behind the scenes video of "Genetics" performance with Nicole Scherzinger of – LaineyGossip

April 24th, 2020 5:46 pm

Like everyone else, Im consuming everything in sight these days, because what else are we going to do, really; but also like everyone else (I suspect) Im using the time either to catch up on series I heard I should have watched, or to be pulled into whatever Netflix serves me up.

Then the other day, @ceas89 sent us a video on Twitter, and I was enthralled and also ashamed. Enthralled because it was amazing; ashamed because before now, I didnt know. The video is a behind the scenes of Trainors song Genetics, featuring Nicole Scherzinger of the Pussycat Dolls, and before I clicked, I read the tweet, which said, can you please talk about the work happening in this video? So, I played it (skip to 0:30 to really get to the goods):

The song was released in September 2019, but Meghan posted it just a couple of weeks ago. And, as @ceas89 predicted, I watched it over and over, because its incredible. And Ill confess, I didnt know this work was gonna be here. I love that theyre recording in an apartment or bungalow of some kind weve seen this kind of video before, but often in a blank, black studio. Somehow I felt more welcomed into the room in this video, which is a cool trick.

But its the dynamics of this that I love most.

Meghan starts off complimenting Nicole, in a way that might seem self-deprecating. I have the voice to record, I just dont have the dance moves to dance. Initially I was sort of frustrated with that, because I felt like the Meghan Trainor doesnt have the right body for the music industry narrative is boring, played out, and also, its patently not true. Ask Lizzo.

But as the rest of the video unfolds, its clear that what shes doing is actually trying to build Nicole up. Because its Meghans song, and she knows how it needs to go, while Nicole is anxiously trying to do her best, but is aware, maybe, that shes not *quite* nailing it. We dont see the takes where she doesnt get her vocals to where they need to be, but her affect and the way she looks at Meghan for reassurance makes it clear.

Trainor builds her up, over and over again, Oh-my-God-ing over Nicoles vocals, but also clearly directing her: what kind of tone, what kind of dynamic. Even from her slumped position on the couch shes commanding, as she tells Nicole sing with me, until its clear that Nicole has gotten it right. Wait she directs Nicole during a vocal run, and then, never missing a beat, reminds her, Its a quick but here.

Then look what happens at 2:41. Meghan lays down some vocals, and Nicole, stunned, comments, Wow, she just does it in one take and then puts her head in her hands. As @ceas89 put it, Nicole is legitimately shook, and its true. Its so easy for you, she comments to Meghan, who laughs. No self-deprecation this time

Because its clearly true. Its easy for Meghan. Its easy for her and necessary for her to tell Nicole how the song needs to be done, because she wrote it. Did you know Meghan Trainor wrote songs? I mean, I guess I assumed she wrote her own songs, but I didnt know shed also written songs for Jason Derulo, Jason Mraz, Faith Hill and Tim McGraw, Michael Bubl, and Jennifer Lopez.

I didnt know. Not really. And I should have.

I loved All About The Bass like everyone else, but as much as I appreciated the retro-bop style, I didnt love the messaging about what boys need, and the follow-ups of Dear Future Husband and Lips Are Moving seemed so retro that I lost interest. Not that Trainor cares her career has been incredibly successful whether or not I like her messaging or packaging or not.

But lets be real: I underestimated Meghan Trainor, maybe because of how she was marketed. I saw her as a gimmicky artist and look, her image does have inherent gimmick-ness to it but I let it cloud me to the phenomenal talent thats gotten her this far, and Im mad at myself for doing it. Why do talented people have to have a certain image? If she was in plaid button-downs and less lipstick in her videos, would I have seen it more? If there were more videos like this out there alongside her cutesy finger-wagging videos?

Im not saying we have to like everyone, and there are millions of talented people, and entire genres of entertainment that are just not for me, the same way some people cant abide musicals, or animation, or non-fiction. But this video was a reminder that even though I think I see through all kinds of showbiz packaging, the stuff I really value hard work, genius-level talent, industry respect is totally separate from the packaging and marketing of an artist, and I let this one slip by me before now. Thank you, @ceas89, for the education.

Whose talent do you think everyone else is sleeping on? (No, Lainey, BTS does not apply here.) Is there someone youve discovered recently, since consuming entertainment has become our collective new job? Do you have a method for exposing yourself to new stuff so you dont make snap judgments like I did? Theres nothing I love more than a celebrity surprise, so if theres someone I, or all of us, should know, hit us up. A new discovery is a delightful comfort and joy right now.

See more here:
Meghan Trainor shows her work in behind the scenes video of "Genetics" performance with Nicole Scherzinger of - LaineyGossip

Read More...

Suspect In 1981 Murder Of 17-Year-Old Sacramento Girl Identified Thanks To Genetic Genealogy – CBS Sacramento

April 24th, 2020 5:46 pm

SACRAMENTO (CBS13) A brutal Sacramento murder case that went cold for nearly four decades has been solved thanks to genetic genealogy, detectives say.

Mary London was a 17-year-old sophomore at Sacramento High School. On the morning of Jan. 15, 1981, her body was found dumped on the side of what once was a rural stretch of San Juan Road; she had been stabbed multiple times, police said.

The case went cold and no suspect was ever identified.

That is until Thursday, when the Sacramento Police Department and Sacramento County District Attorneys Office announced that they had identified a suspect in the case.

Detectives say genetic genealogy and transitional DNA have linked a man named Vernon Parker to crime.

Investigative genetic genealogy has revolutionized law enforcements ability to solve violent crime: to identify the guilty and exonerate the innocent, said District Attorney Anne MarieSchubert in a statement about the case.

No other information, including what may have led up to the killing, was released and Parker was murdered a little over a year after Marys death, detectives say.

Genetic genealogy has helped identify a number of suspects in cases that had gone cold. The technique came to prominence in 2018 when it was credited with helping identify Joseph DeAngelo as the suspect in the Golden State Killer/East Area Rapist case.

Go here to see the original:
Suspect In 1981 Murder Of 17-Year-Old Sacramento Girl Identified Thanks To Genetic Genealogy - CBS Sacramento

Read More...

Gods of genetic engineering: With the end of ‘Homo sapiens naturalis’ approaching, what is our place in nature? – Genetic Literacy Project

April 24th, 2020 5:46 pm

Our society has evolved so much, can we still say that we are part of Nature? If not, should we worry and what should we do about it? Poppy, 21, Warwick.

Such is the extent of our dominion on Earth, that the answer to questions around whether we are still part of nature and whether we even need some of it rely on an understanding of what we want as Homo sapiens. And to know what we want, we need to grasp what we are.

It is a huge question but they are the best. And as a biologist, here is my humble suggestion to address it, and a personal conclusion. You may have a different one, but what matters is that we reflect on it.

Perhaps the best place to start is to consider what makes us human in the first place, which is not as obvious as it may seem.

Many years ago, a novel written by Vercors called Les Animaux dnaturs (Denatured Animals) told the story of a group of primitive hominids, the Tropis, found in an unexplored jungle in New Guinea, who seem to constitute a missing link.

However, the prospect that this fictional group may be used as slave labor by an entrepreneurial businessman named Vancruysen forces society to decide whether the Tropis are simply sophisticated animals or whether they should be given human rights. And herein lies the difficulty.

Human status had hitherto seemed so obvious that the book describes how it is soon discovered that there is no definition of what a human actually is. Certainly, the string of experts consulted anthropologists, primatologists, psychologists, lawyers and clergymen could not agree. Perhaps prophetically, it is a layperson who suggested a possible way forward.

She asked whether some of the hominids habits could be described as the early signs of a spiritual or religious mind. In short, were there signs that, like us, the Tropis were no longer at one with nature, but had separated from it, and were now looking at it from the outside with some fear.

It is a telling perspective. Our status as altered or denatured animals creatures who have arguably separated from the natural world is perhaps both the source of our humanity and the cause of many of our troubles. In the words of the books author:

All mans troubles arise from the fact that we do not know what we are and do not agree on what we want to be.

We will probably never know the timing of our gradual separation from nature although cave paintings perhaps contain some clues. But a key recent event in our relationship with the world around us is as well documented as it was abrupt. It happened on a sunny Monday morning, at 8.15am precisely.

The atomic bomb that rocked Hiroshima on August 6 1945, was a wake-up call so loud that it still resonates in our consciousness many decades later.

The day the sun rose twice was not only a forceful demonstration of the new era that we had entered, it was a reminder of how paradoxically primitive we remained: differential calculus, advanced electronics and almost godlike insights into the laws of the universe helped build, well a very big stick. Modern Homo sapiens seemingly had developed the powers of gods, while keeping the psyche of a stereotypical Stone Age killer.

We were no longer fearful of nature, but of what we would do to it, and ourselves. In short, we still did not know where we came from, but began panicking about where we were going.

We now know a lot more about our origins but we remain unsure about what we want to be in the future or, increasingly, as the climate crisis accelerates, whether we even have one.

Arguably, the greater choices granted by our technological advances make it even more difficult to decide which of the many paths to take. This is the cost of freedom.

I am not arguing against our dominion over nature nor, even as a biologist, do I feel a need to preserve the status quo. Big changes are part of our evolution. After all, oxygen was first a poison which threatened the very existence of early life, yet it is now the fuel vital to our existence.

Similarly, we may have to accept that what we do, even our unprecedented dominion, is a natural consequence of what we have evolved into, and by a process nothing less natural than natural selection itself. If artificial birth control is unnatural, so is reduced infant mortality.

I am also not convinced by the argument against genetic engineering on the basis that it is unnatural. By artificially selecting specific strains of wheat or dogs, we had been tinkering more or less blindly with genomes for centuries before the genetic revolution. Even our choice of romantic partner is a form of genetic engineering. Sex is natures way of producing new genetic combinations quickly.

Even nature, it seems, can be impatient with itself.

Advances in genomics, however, have opened the door to another key turning point. Perhaps we can avoid blowing up the world, and instead change it and ourselves slowly, perhaps beyond recognition.

The development of genetically modified crops in the 1980s quickly moved from early aspirations to improve the taste of food to a more efficient way of destroying undesirable weeds or pests.

In what some saw as the genetic equivalent of the atomic bomb, our early forays into a new technology became once again largely about killing, coupled with worries about contamination. Not that everything was rosy before that. Artificial selection, intensive farming and our exploding population growth were long destroying species quicker than we could record them.

The increasing silent springs of the 1950s and 60s caused by the destruction of farmland birds and, consequently, their song was only the tip of a deeper and more sinister iceberg. There is, in principle, nothing unnatural about extinction, which has been a recurring pattern (of sometimes massive proportions) in the evolution of our planet long before we came on the scene. But is it really what we want?

The arguments for maintaining biodiversity are usually based on survival, economics or ethics. In addition to preserving obvious key environments essential to our ecosystem and global survival, the economic argument highlights the possibility that a hitherto insignificant lichen, bacteria or reptile might hold the key to the cure of a future disease. We simply cannot afford to destroy what we do not know.

But attaching an economic value to life makes it subject to the fluctuation of markets. It is reasonable to expect that, in time, most biological solutions will be able to be synthesized, and as the market worth of many lifeforms falls, we need to scrutinize the significance of the ethical argument. Do we need nature because of its inherent value?

Perhaps the answer may come from peering over the horizon. It is somewhat of an irony that as the third millennium coincided with decrypting the human genome, perhaps the start of the fourth may be about whether it has become redundant.

Just as genetic modification may one day lead to the end of Homo sapiens naturalis (that is, humans untouched by genetic engineering), we may one day wave goodbye to the last specimen of Homo sapiens genetica. That is the last fully genetically based human living in a world increasingly less burdened by our biological form minds in a machine.

If the essence of a human, including our memories, desires and values, is somehow reflected in the pattern of the delicate neuronal connections of our brain (and why should it not?) our minds may also one day be changeable like never before.

And this brings us to the essential question that surely we must ask ourselves now: if, or rather when, we have the power to change anything, what would we not change?

After all, we may be able to transform ourselves into more rational, more efficient and stronger individuals. We may venture out further, have greater dominion over greater areas of space, and inject enough insight to bridge the gap between the issues brought about by our cultural evolution and the abilities of a brain evolved to deal with much simpler problems. We might even decide to move into a bodiless intelligence: in the end, even the pleasures of the body are located in the brain.

And then what? When the secrets of the universe are no longer hidden, what makes it worth being part of it? Where is the fun?

Gossip and sex, of course! some might say. And in effect, I would agree (although I might put it differently), as it conveys to me the fundamental need that we have to reach out and connect with others. I believe that the attributes that define our worth in this vast and changing universe are simple: empathy and love. Not power or technology, which occupy so many of our thoughts but which are merely (almost boringly) related to the age of a civilization.

Like many a traveler, Homo sapiens may need a goal. But from the strengths that come with attaining it, one realizes that ones worth (whether as an individual or a species) ultimately lies elsewhere. So I believe that the extent of our ability for empathy and love will be the yardstick by which our civilization is judged. It may well be an important benchmark by which we will judge other civilizations that we may encounter, or indeed be judged by them.

There is something of true wonder at the basis of it all. The fact that chemicals can arise from the austere confines of an ancient molecular soup, and through the cold laws of evolution, combine into organisms that care for other lifeforms (that is, other bags of chemicals) is the true miracle.

Some ancients believed that God made us in his image. Perhaps they were right in a sense, as empathy and love are truly godlike features, at least among the benevolent gods.

Cherish those traits and use them now, Poppy, as they hold the solution to our ethical dilemma. It is those very attributes that should compel us to improve the wellbeing of our fellow humans without lowering the condition of what surrounds us.

Anything less will pervert (our) nature.

Manuel Berdoy is a biologist at the University of Oxford

A version of this article originally appeared on The Conversation and has been republished here with permission. The Conversation can be found on Twitter @ConversationUS

Link:
Gods of genetic engineering: With the end of 'Homo sapiens naturalis' approaching, what is our place in nature? - Genetic Literacy Project

Read More...

Reversing diabetes with CRISPR and patient-derived stem cells – FierceBiotech

April 24th, 2020 5:44 pm

Insulin injections cancontrol diabetes, but patients still experience serious complications such as kidney disease and skin infections. Transplanting pancreatic tissues containing functional insulin-producing beta cells is of limited use, because donors are scarce and patients must take immunosuppressant drugs afterward.

Now, scientists atWashington University in St. Louis havedeveloped a way to use gene editing system CRISPR-Cas9 to edit a mutation in human-induced pluripotent stem cells (iPSCs) and then turnthem into beta cells. When transplanted into mice, the cells reversed preexisting diabetes in a lasting way, according to results published in the journal Science Translational Medicine.

While the researchers used cells from patients with Wolfram syndromea rare childhood diabetes caused by mutations in the WFS1 genethey argue that the combination of a gene therapy with stem cells could potentially treat other forms of diabetes as well.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

One of the biggest challenges we faced was differentiating our patient cells into beta cells. Previous approaches do not allow for this robust differentiation. We use our new differentiation protocol targeting different development and signaling pathways to generate our cells, the studys lead author, Kristina Maxwell, explained in a video statement.

Making pancreatic beta cells from patient-derived stem cells requires precise activation and repression of specific pathways, and atthe right times, to guide the development process. In a recent Nature Biotechnology study, the team described a successful method that leverages the link between a complex known as actin cytoskeleton and the expression of transcription factors that drive pancreatic cell differentiation.

This time, the researchers applied the technology to iPSCs from two patients with Wolfram syndrome. They used CRISPR to correct the mutated WFS1 gene in the cells and differentiated the edited iPSCs into fully functional beta cells.

After transplanting the corrected beta cells into diabetic mice, the animals saw their blood glucose drop quickly, suggesting the disease had been reversed. The effect lasted for the entire six-month observation period, the scientists reported. By comparison, those receiving unedited cells from patients were unable to achieve glycemic control.

RELATED:CRISPR Therapeutics, ViaCyte team up on gene-edited diabetes treatment

The idea of editing stem cells with CRISPR has already attracted interest in the biopharma industry. Back in 2018, CRISPR Therapeutics penned a deal with ViaCyte to develop off-the-shelf, gene-editing stem cell therapies for diabetes. Rather than editing iPSCs from particular patients themselves to correct a faulty gene, the pairs lead project used CRISPR to edit healthy cells so that they lackedthe B2M gene and expressed PD-L1 to protect against immune attack. The two companies unveiled positive preclinical data inSeptember.

Other research groups working on gene therapy or stem cells for diabetes include a Harvard University scientist and his startup Semma Therapeutics, whichdeveloped a method for selecting beta cells out of a mixture of cells developed from PSCs. Scientists at the University of Wisconsin-Madison recently proposed that removing the IRE1-alpha gene in beta cells could prevent immune T cells from attacking them in mice with Type 1 diabetes.

The Washington University team hopes its technology may help Type 1 diabetes patients whose disease is caused by multiple genetic and environmental factors as well as the Type 2 form linked to obesity and insulin resistance.

We can generate a virtually unlimited number of beta cells from patients with diabetes to test and discover new drugs to hopefully stop or even reverse this disease, Jeffrey Millman, the studys co-senior author, said in the video statement. Perhaps most importantly, this technology now allows for the potential use of gene therapy in combination with the patients own cells to treat their own diabetes by transplantation of lab-grown beta cells.

Continue reading here:
Reversing diabetes with CRISPR and patient-derived stem cells - FierceBiotech

Read More...

How effective is PLX cell therapy in treating coronavirus? Experts answer all queries and more – India TV News

April 24th, 2020 5:44 pm

Pluristem Therapeutics or PLX cell therapyuses placentas to grow smart cells, and programs them to secrete therapeutic proteins in the bodies of sick people. It has just treated its first American COVID-19 patient after treating seven Israelis. The patients were suffering from acute respiratory failure and inflammatory complications associated with Covid-19. Now, this theraphy is being touted as a possible 'cure'' for the deadly coronavirus with scientisst conducting varied researches on the same. In an exclusive interaction with India TV, doctors from India and abroadcame together for discussing about how effective can cell therapy be in treating coronavirus. Dr Solomon from Israel, Dr Anil Kaul from the US, DrSanjeev Chaubey from Shanghai and Dr Padma Srivastv and Dr Harsh Mahajan from India threw light upon the stem cell therapy and the possibility of incorporating the same in treating COVID-19 pateints.

Latest News on Coronavirus

Fight against Coronavirus: Full coverage

Read the original here:
How effective is PLX cell therapy in treating coronavirus? Experts answer all queries and more - India TV News

Read More...

Discovered the physiological mechanisms underlying the most common pediatric Leukemia – Science Codex

April 24th, 2020 5:44 pm

B-cell acute lymphoblastic leukemia (B-ALL) is characterized by the accumulation of abnormal immature B-cell precursors (BCP) in the bone marrow (BM) and is the most common pediatric cancer. Among the different subtypes known in B-ALL, the most common one is characterized by the presence of a higher number of chromosomes than in healthy cells and is called High hyperdiploid B-ALL (HyperD-ALL). This genetic abnormality is an initiating oncogenic event affiliated to childhood B-ALL, and it remains poorly characterized.

HyperD-ALL comprises 30% of pediatric B-ALL and usually has a favorable clinical outcome, with 90% of survival in patients with this hematologic cancer. Despite this, until date, there was very little knowledge on how hyperdiploidy occurs in HyperD-ALL, as an initiating oncogenic event in B-ALL and which secondary alterations are necessary for leukemic B-ALL cells accumulation in the bone marrow, impeding the growth of healthy cells and leading to the clinical leukemia complications.

A precise knowledge of the physiopathogenic mechanisms underlying HyperD- ALL was necessary because the morbidity/mortality associated with HyperD-ALL still represents a clinical challenge due to the high number of patients suffering from this type of B-ALL. For this reason, Oscar Molina, researcher of the Group of Stem Cells, Developmental Biology, and Immunotherapy of the Josep Carreras Leukaemia Research Institute, has led research on the mechanisms underlying HyperD-ALL, unveiling how and why it happens, published in Blood Journal this April 2020.

Molina and the co-authors of the study hypothesized that the origin of the pathogenic mechanisms associated with hyperdiploidy in B-ALL could be in the moment of the cell's division, known as mitosis, which is a highly orchestrated cellular process that controls the equal distribution of the genetic material, already duplicated and compacted in chromosomes, in two "newborn" cells.

"We knew already that HyperD-ALL arises in a BCP in utero. However, the causal molecular mechanisms of hyperdiploidy in BCPs remained elusive. As faithful chromosome segregation is essential for maintaining the genomic integrity of cells, and deficient chromosome segregation leads to aneuploidy and cancer, we wanted to observe and deepen on what is happening in chromosomes' segregation in HyperD-ALL, because we suspected that by studying cell division in these cells we would find an explanation to this oncogenic process."

Molina was right. Researchers used a large cohort of primary pediatric B-ALL samples, 54. What Molina and his colleagues discovered was that three key processes and actors for correct mitosis or cell division and chromosome segregation were misfunctioning in hyperdiploid cells; that artificial disruption of these processes in blood cells with normal chromosome numbers generated hyperdiploid cells resembling those in B-ALL samples. Therefore, shedding light on the cellular and molecular mechanisms involved in HyperD-ALL origin and progression.

The main proteins and processes leading to fatal error were a malfunctioning of the Condensin complex, a multiprotein complex responsible for helping condense the genetic material correctly into chromosomes; the protein Aurora B kinase, that is responsible for a correct chromosome attachment to the spindle poles, thus ensuring proper chromosome segregation; and the mitotic checkpoint, or Spindle Assembly Checkpoint (SAC), the cell machinery involved in controlling that chromosomes are correctly separated to each pole of the cell that is dividing.

With these findings, Molina et al. have unveiled the molecular mechanisms that are altered in this frequent type of pediatric blood cancer.

"Next steps would be to study whether other subtypes of B-ALL with abnormal chromosome numbers, such as hypodiploid B-ALL, a very aggressive subtype of pediatric blood cancer characterized by lower numbers of chromosomes, share a common molecular mechanism. These studies will allow generating the first in vivo models of leukemias with abnormal chromosome numbers in mice that will be crucial to understand its origin and development, thus facilitating the development of more targeted and less toxic therapies for these pediatric blood cancers" stated Oscar Molina.

Here is the original post:
Discovered the physiological mechanisms underlying the most common pediatric Leukemia - Science Codex

Read More...

A rampage through the body – Science Magazine

April 24th, 2020 5:44 pm

The lungs are ground zero, but COVID-19 also tears through organ systems from brain to blood vessels.

Science's COVID-19 coverage is supported by the Pulitzer Center.

The coronavirus wreaked extensive damage (yellow) on the lungs of a 59-year-old man who died at George Washington University Hospital, as seen in a 3D model based on computed tomography scans.

On rounds in a 20-bed intensive care unit one recent day, physician Joshua Denson assessed two patients with seizures, many with respiratory failure, and others whose kidneys were on a dangerous downhill slide. Days earlier, his rounds had been interrupted as his team tried, and failed, to resuscitate a young woman whose heart had stopped. All of the patients shared one thing, says Denson, a pulmonary and critical care physician at the Tulane University School of Medicine. They are all COVID positive.

As the number of confirmed cases of COVID-19 approaches 2.5 million globally and deaths surpass 166,000, clinicians and pathologists are struggling to understand the damage wrought by the coronavirus as it tears through the body. They are realizing that although the lungs are ground zero, the virus' reach can extend to many organs including the heart and blood vessels, kidneys, gut, and brain.

[The disease] can attack almost anything in the body with devastating consequences, says cardiologist Harlan Krumholz of Yale University and Yale-New Haven Hospital, who is leading multiple efforts to gather clinical data on COVID-19. Its ferocity is breathtaking and humbling.

Understanding the rampage could help doctors on the front lines treat the roughly 5% of infected people who become desperately and sometimes mysteriously ill. Does a dangerous, newly observed tendency to blood clotting transform some mild cases into life-threatening emergencies? Is an overzealous immune response behind the worst cases, suggesting treatment with immune-suppressing drugs could help? And what explains the startlingly low blood oxygen that some physicians are reporting in patients who nonetheless are not gasping for breath? Taking a systems approach may be beneficial as we start thinking about therapies, says Nilam Mangalmurti, a pulmonary intensivist at the Hospital of the University of Pennsylvania (HUP).

What follows is a snapshot of the fast-evolving understanding of how the virus attacks cells around the body. Despite the more than 1500 papers now spilling into journals and onto preprint servers every week, a clear picture is elusive, as the virus acts like no pathogen humanity has ever seen. Without larger, controlled studies that are only now being launched, scientists must pull information from small studies and case reports, often published at warp speed and not yet peer reviewed. We need to keep a very open mind as this phenomenon goes forward, says Nancy Reau, a liver transplant physician who has been treating COVID-19 patients at Rush University Medical Center. We are still learning.

WHEN AN INFECTED PERSON expels virus-laden droplets and someone else inhales them, the novel coronavirus, called SARS-CoV-2, enters the nose and throat. It finds a welcome home in the lining of the nose, according to a recent arXiv preprint, because cells there are rich in a cell-surface receptor called angiotensin-converting enzyme 2 (ACE2). Throughout the body, the presence of ACE2, which normally helps regulate blood pressure, marks tissues potentially vulnerable to infection, because the virus requires that receptor to enter a cell. Once inside, the virus hijacks the cell's machinery, making myriad copies of itself and invading new cells.

As the virus multiplies, an infected person may shed copious amounts of it, especially during the first week or so. Symptoms may be absent at this point. Or the virus' new victim may develop a fever, dry cough, sore throat, loss of smell and taste, or head and body aches.

If the immune system doesn't beat back SARS-CoV-2 during this initial phase, the virus then marches down the windpipe to attack the lungs, where it can turn deadly. The thinner, distant branches of the lung's respiratory tree end in tiny air sacs called alveoli, each lined by a single layer of cells that are also rich in ACE2 receptors.

Normally, oxygen crosses the alveoli into the capillaries, tiny blood vessels that lie beside the air sacs; the oxygen is then carried to the rest of the body. But as the immune system wars with the invader, the battle itself disrupts healthy oxygen transfer. Frontline white blood cells release inflammatory molecules called chemokines, which in turn summon more immune cells that target and kill virus-infected cells, leaving a stew of fluid and dead cellspusbehind (see graphic, below). This is the underlying pathology of pneumonia, with its corresponding symptoms: coughing; fever; and rapid, shallow respiration. Some COVID-19 patients recover, sometimes with no more support than oxygen breathed in through nasal prongs.

But others deteriorate, often suddenly, developing a condition called acute respiratory distress syndrome. Oxygen levels in their blood plummet, and they struggle ever harder to breathe. On x-rays and computed tomography scans, their lungs are riddled with white opacities where black spaceairshould be. Commonly, these patients end up on ventilators. Many die, and survivors may face long-term complications (see sidebar, p. 359). Autopsies show their alveoli became stuffed with fluid, white blood cells, mucus, and the detritus of destroyed lung cells.

Some clinicians suspect the driving force in many gravely ill patients' downhill trajectories is a disastrous overreaction of the immune system known as a cytokine storm, which other viral infections are known to trigger. Cytokines are chemical signaling molecules that guide a healthy immune response; but in a cytokine storm, levels of certain cytokines soar far beyond what's needed, and immune cells start to attack healthy tissues. Blood vessels leak, blood pressure drops, clots form, and catastrophic organ failure can ensue.

Some studies have shown elevated levels of these inflammation-inducing cytokines in the blood of hospitalized COVID-19 patients. The real morbidity and mortality of this disease is probably driven by this out of proportion inflammatory response to the virus, says Jamie Garfield, a pulmonologist who cares for COVID-19 patients at Temple University Hospital.

But others aren't convinced. There seems to have been a quick move to associate COVID-19 with these hyperinflammatory states. I haven't really seen convincing data that that is the case, says Joseph Levitt, a pulmonary critical care physician at the Stanford University School of Medicine.

He's also worried that efforts to dampen a cytokine response could backfire. Several drugs targeting specific cytokines are in clinical trials in COVID-19 patients. But Levitt fears those drugs may suppress the immune response that the body needs to fight off the virus. There's a real risk that we allow more viral replication, Levitt says.

Meanwhile, other scientists are zeroing in on an entirely different organ system that they say is driving some patients' rapid deterioration: the heart and blood vessels.

IN BRESCIA, ITALY, a 53-year-old woman walked into the emergency room of her local hospital with all the classic symptoms of a heart attack, including telltale signs in her electrocardiogram and high levels of a blood marker suggesting damaged cardiac muscles. Further tests showed cardiac swelling and scarring, and a left ventriclenormally the powerhouse chamber of the heartso weak that it could only pump one-third its normal amount of blood. But when doctors injected dye in her coronary arteries, looking for the blockage that signifies a heart attack, they found none. Another test revealed the real cause: COVID-19.

How the virus attacks the heart and blood vessels is a mystery, but dozens of preprints and papers attest that such damage is common. A 25 March paper in JAMA Cardiology found heart damage in nearly 20% of patients out of 416 hospitalized for COVID-19 in Wuhan, China. In another Wuhan study, 44% of 36 patients admitted to the intensive care unit (ICU) had arrhythmias.

The disruption seems to extend to the blood itself. Among 184 COVID-19 patients in a Dutch ICU, 38% had blood that clotted abnormally, and almost one-third already had clots, according to a 10 April paper in Thrombosis Research. Blood clots can break apart and land in the lungs, blocking vital arteriesa condition known as pulmonary embolism, which has reportedly killed COVID-19 patients. Clots from arteries can also lodge in the brain, causing stroke. Many patients have dramatically high levels of D-dimer, a byproduct of blood clots, says Behnood Bikdeli, a cardiovascular medicine fellow at Columbia University Medical Center.

The more we look, the more likely it becomes that blood clots are a major player in the disease severity and mortality from COVID-19, Bikdeli says.

Infection may also lead to blood vessel constriction. Reports are emerging of ischemia in the fingers and toesa reduction in blood flow that can lead to swollen, painful digits and tissue death.

In the lungs, blood vessel constriction might help explain anecdotal reports of a perplexing phenomenon seen in pneumonia caused by COVID-19: Some patients have extremely low blood-oxygen levels and yet are not gasping for breath. In this scenario, oxygen uptake is impeded by constricted blood vessels rather than by clogged alveoli. One theory is that the virus affects the vascular biology and that's why we see these really low oxygen levels, Levitt says.

If COVID-19 targets blood vessels, that could also help explain why patients with pre-existing damage to those vessels, for example from diabetes and high blood pressure, face higher risk of serious disease. Recent Centers for Disease Control and Prevention (CDC) data on hospitalized patients in 14 U.S. states found that about one-third had chronic lung diseasebut nearly as many had diabetes, and fully half had pre-existing high blood pressure.

Mangalmurti says she has been shocked by the fact that we don't have a huge number of asthmatics or patients with other respiratory diseases in her hospital's ICU. It's very striking to us that risk factors seem to be vascular: diabetes, obesity, age, hypertension.

Scientists are struggling to understand exactly what causes the cardiovascular damage. The virus may directly attack the lining of the heart and blood vessels, which, like the nose and alveoli, are rich in ACE2 receptors. By altering the delicate balance of hormones that help regulate blood pressure, the virus might constrict blood vessels going to the lungs. Another possibility is that lack of oxygen, due to the chaos in the lungs, damages blood vessels. Or a cytokine storm could ravage the heart as it does other organs.

We're still at the beginning, Krumholz says. We really don't understand who is vulnerable, why some people are affected so severely, why it comes on so rapidly and why it is so hard [for some] to recover.

THE WORLDWIDE FEARS of ventilator shortages for failing lungs have received plenty of attention. Not so a scramble for another type of equipment: kidney dialysis machines. If these folks are not dying of lung failure, they're dying of renal failure, says neurologist Jennifer Frontera of New York University's Langone Medical Center, which has treated thousands of COVID-19 patients. Her hospital is developing a dialysis protocol with a different kind of machine to support more patients. What she and her colleagues are seeing suggests the virus may target the kidneys, which are abundantly endowed with ACE2 receptors.

According to one preprint, 27% of 85 hospitalized patients in Wuhan had kidney failure. Another preprint reported that 59% of nearly 200 hospitalized COVID-19 patients in China's Hubei and Sichuan provinces had protein in their urine, and 44% had blood; both suggest kidney damage. Those with acute kidney injury were more than five times as likely to die as COVID-19 patients without it, that preprint reported.

The lung is the primary battle zone. But a fraction of the virus possibly attacks the kidney. And as on the real battlefield, if two places are being attacked at the same time, each place gets worse, says co-author Hongbo Jia, a neuroscientist at the Chinese Academy of Sciences's Suzhou Institute of Biomedical Engineering and Technology.

One study identified viral particles in electron micrographs of kidneys from autopsies, suggesting a direct viral attack. But kidney injury may also be collateral damage. Ventilators boost the risk of kidney damage, as do antiviral compounds including remdesivir, which is being deployed experimentally in COVID-19 patients. Cytokine storms can also dramatically reduce blood flow to the kidney, causing often-fatal damage. And pre-existing diseases like diabetes can increase the chances of kidney injury. There is a whole bucket of people who already have some chronic kidney disease who are at higher risk for acute kidney injury, says Suzanne Watnick, chief medical officer at Northwest Kidney Centers.

ANOTHER STRIKING SET of symptoms in COVID-19 patients centers on the brain and nervous system. Frontera says 5% to 10% of coronavirus patients at her hospital have neurological symptoms. But she says that is probably a gross underestimate of the number whose brains are struggling, especially because many are sedated and on ventilators.

Frontera has seen patients with the brain inflammation encephalitis, seizures, and a sympathetic storm, a hyperreaction of the sympathetic nervous system that causes seizurelike symptoms and is most common after a traumatic brain injury. Some people with COVID-19 briefly lose consciousness. Others have strokes. Many report losing their sense of smell and taste. And Frontera and others wonder whether, in some cases, infection depresses the brain stem reflex that senses oxygen starvationanother explanation for anecdotal observations that some patients aren't gasping for air, despite dangerously low blood oxygen levels.

ACE2 receptors are present in the neural cortex and brain stem, says Robert Stevens, an intensive care physician at Johns Hopkins Medicine. And the coronavirus behind the 2003 severe acute respiratory syndrome (SARS) epidemica close cousin of today's culpritwas able to infiltrate neurons and sometimes caused encephalitis. On 3 April, a case study in the International Journal of Infectious Diseases, from a team in Japan, reported traces of new coronavirus in the cerebrospinal fluid of a COVID-19 patient who developed meningitis and encephalitis, suggesting it, too, can penetrate the central nervous system.

But other factors could be damaging the brain. For example, a cytokine storm could cause brain swelling. The blood's exaggerated tendency to clot could trigger strokes. The challenge now is to shift from conjecture to confidence, at a time when staff are focused on saving lives, and even neurologic assessments like inducing the gag reflex or transporting patients for brain scans risk spreading the virus.

Last month, Sherry Chou, a neurologist at the University of Pittsburgh Medical Center, began to organize a worldwide consortium that now includes 50 centers to draw neurological data from care patients already receive. Early goals are simple: Identify the prevalence of neurologic complications in hospitalized patients and document how they fare. Longer term, Chou and her colleagues hope to gather scans and data from lab tests to better understand the virus' impact on the nervous system, including the brain.

No one knows when or how the virus might penetrate the brain. But Chou speculates about a possible invasion route: through the nose, then upward and through the olfactory bulbexplaining reports of a loss of smellwhich connects to the brain. It's a nice sounding theory, she says. We really have to go and prove that.

A 58-year-old woman with COVID-19 developed encephalitis, with tissue damage in the brain (arrows).

Most neurological symptoms are reported from colleague to colleague by word of mouth, Chou adds. I don't think anybody, and certainly not me, can say we're experts.

IN EARLY MARCH, a 71-year-old Michigan woman returned from a Nile River cruise with bloody diarrhea, vomiting, and abdominal pain. Initially doctors suspected she had a common stomach bug, such as Salmonella. But after she developed a cough, doctors took a nasal swab and found her positive for the novel coronavirus. A stool sample positive for viral RNA, as well as signs of colon injury seen in an endoscopy, pointed to a gastrointestinal (GI) infection with the coronavirus, according to a paper posted online in The American Journal of Gastroenterology (AJG).

Her case adds to a growing body of evidence suggesting the new coronavirus, like its cousin SARS, can infect the lining of the lower digestive tract, where ACE2 receptors are abundant. Viral RNA has been found in as many as 53% of sampled patients' stool samples. And in a paper in press at Gastroenterology, a Chinese team reported finding the virus' protein shell in gastric, duodenal, and rectal cells in biopsies from a COVID-19 patient. I think it probably does replicate in the gastrointestinal tract, says Mary Estes, a virologist at Baylor College of Medicine.

Recent reports suggest up to half of patients, averaging about 20% across studies, experience diarrhea, says Brennan Spiegel of Cedars-Sinai Medical Center in Los Angeles, coeditor-in-chief of AJG. GI symptoms aren't on CDC's list of COVID-19 symptoms, which could cause some COVID-19 cases to go undetected, Spiegel and others say. If you mainly have fever and diarrhea, you won't be tested for COVID, says Douglas Corley of Kaiser Permanente, Northern California, co-editor of Gastroenterology.

The presence of virus in the GI tract raises the unsettling possibility that it could be passed on through feces. But it's not yet clear whether stool contains intact, infectious virus, or only RNA and proteins. To date, We have no evidence that fecal transmission is important, says coronavirus expert Stanley Perlman of the University of Iowa. CDC says that, based on experiences with SARS and with the coronavirus that causes Middle East respiratory syndrome, the risk from fecal transmission is probably low.

The intestines are not the end of the disease's march through the body. For example, up to one-third of hospitalized patients develop conjunctivitispink, watery eyesalthough it's not clear that the virus directly invades the eye.

Other reports suggest liver damage: More than half of COVID-19 patients hospitalized in two Chinese centers had elevated levels of enzymes indicating injury to the liver or bile ducts. But several experts told Science that direct viral invasion isn't likely the culprit. They say other events in a failing body, like drugs or an immune system in overdrive, are more likely causes of the liver damage.

This map of the devastation that COVID-19 can inflict on the body is still just a sketch. It will take years of painstaking research to sharpen the picture of its reach, and the cascade of effects in the body's complex and interconnected systems that it might set in motion. As science races ahead, from probing tissues under microscopes to testing drugs on patients, the hope is for treatments more wily than the virus that has stopped the world in its tracks.

Read the rest here:
A rampage through the body - Science Magazine

Read More...

NHS’s oldest IVF clinic at risk of closure amid increasing privatisations – The Guardian

April 24th, 2020 5:44 pm

The UKs oldest NHS fertility clinic is at risk of closure and another has been put out to private tender, as IVF provision is increasingly privatised and rationed.

Hospital bosses want to close the internationally renowned department of reproductive medicine at St Marys hospital, Manchester, saying they cannot afford to fund a 10m upgrade of the unit, the Guardian has learned.

In Leeds, the entire NHS provision of fertility and other gynaecology services was put out to tender earlier this year, with private clinics invited to bid for a 10-year contract estimated at 70m to provide reproductive care.

Two years ago North Bristol NHS trust sold off its IVF clinic to a private provider, saying it was no longer feasible because of a reduction in NHS-funded patients.

In England, the proportion of fertility treatment funded by the NHS dropped from 39% in 2012 to 35% in 2017, according to figures published last year by the regulator, the Human Fertilisation and Embryology Authority (HFEA). This is at odds with the rest of the UK, where public funding has remained stable or increased.

When it opened in 1982, four years after the first test tube baby, Louise Brown, was born in nearby Oldham, St Marys was the UKs first fully NHS funded IVF unit. It now performs over 2,000 fertility treatments every year, including around 1,200 IVF cycles, and offers highly specialised fertility preservation for cancer patients. It is also a top research centre, which led on the use of ovarian reserve tests to guide ovarian stimulation, the development of stem cell lines from human embryos, and the effects of IVF on baby birth weights.

The Manchester University NHS foundation trust (MFT) said no decisions had been made over the units future. But staff were briefed last month that the HFEA and local clinical commissioning groups (CCGs) had been told that all licensed treatment and research on the site may end by April 2021 if an alternative solution cannot be found.

MFT, which runs the hospital, is also exploring options including redeploying services and some of its 107 staff including many highly specialised roles but confirmed to staff that closure was a possibility.

The Guardian spoke to 10 members of staff at St Marys aware of the mooted closure. One said they understood the matter to be settled: St Marys have taken a proposal to the MFT group board to discontinue the IVF service and the group board have said, Yes, OK. How they discontinue it is what they need to decide next, they said.

If the change goes ahead, CCGs, which fund fertility treatment, will have to pay private clinics to carry out IVF and other fertility services. But staff at St Marys warn that the private sector will not be able to carry out some of the most specialised services currently offered by the NHS.

We offer highly specialised procedures in the NHS which private providers wont touch because they dont make money and are too difficult. For example, we aim to see women diagnosed with cancer within a week who want to freeze their eggs before they start chemotherapy. Many of these women are already very poorly and need really high quality anaesthetic care during egg collection, and that is just not available in the private sector because of the medical complications, said one source.

They added: Private clinics are also unlikely to help patients with kidney problems or heart problems. But when they come to us, we can address these issues before they begin IVF: a huge advantage of being part of a multi-disciplinary NHS Trust. Those patients will be disadvantaged if this happens.

They also expressed concerns about screening procedures in the private sector. In the NHS, anyone applying for fertility treatment undergoes a series of stringent checks, including an assessment of the welfare of the child: Our checks and ethics advisory committee often flag issues including prison sentences, a serious history of domestic violence, even people on the sex offender register. At private clinics they dont do anything like the same background checks.

A number of separate proposals were put to MFT to try to save some or all of the clinic, including turning the service into a social enterprise and forming a partnership with a private provider, as is being proposed in Leeds.

The deadline to apply to run the Leeds service was 23 March, the day the government announced the coronavirus lockdown in the UK. Shortly afterwards, clinics stopped all new treatments and the HFEA ordered private and NHS clinics to stop treating patients in the middle of an IVF cycle by 15 April.

A spokesperson for the MFT, which runs St Marys hospital, said no decision had been taken to shut the clinic permanently.

They said: Services provided by the department of reproductive medicine at St Marys hospital are regularly reviewed as part of a usual cycle to ensure that we continue to provide the best possible care and treatments for all our service users. No decisions have been made, therefore it would be inappropriate to provide any further detail before the outcome of any review has been finalised.

The HFEA said it could not disclose informal discussions between clinics and inspectors.

Many St Marys staff are worried not just about their patients and their jobs, but the logistics of closing down the clinic. Moving thousands of sperm samples and embryos held in freezers, for use in both treatment and research, was a mind-boggling challenge, said one.

One staff member said: Although possible relocation was mentioned, the fact that no viable alternative has been identified and that the cost was described as being too high left us thinking that this is not being explored and that closing the unit is the direction of travel. We are worried for our jobs but our biggest concern is for our patients, particularly those with the most complex needs who cannot be served elsewhere without high costs.

IVF provision has been put under pressure, nationally, by NHS funding cuts over the past decade leading to a postcode lottery of provision. Now only a minority of English CCGs offer the recommended three funded IVF cycles, with some refusing to fund any NHS fertility treatment at all.

Read more here:
NHS's oldest IVF clinic at risk of closure amid increasing privatisations - The Guardian

Read More...

Vir Biotechnology (VIR): Stock on the Move – Investor Welcome

April 23rd, 2020 1:46 pm

Volatility in Focus:

The stock unfolded volatility at 6.97% during a week and it has been swapped around 11.65% over a month. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Volatility is measured by calculating the standard deviation of the annualized returns over a given period of time. It shows the range to which the price of a security may increase or decrease. Volatility measures the risk of a security. It is used in option pricing formula to gauge the fluctuations in the returns of the underlying assets. Volatility indicates the pricing behavior of the security and helps estimate the fluctuations that may happen in a short period of time. If the prices of a security fluctuate rapidly in a short time span, it is termed to have high volatility. If the prices of a security fluctuate slowly in a longer time span, it is termed to have low volatility.

The average true range is a volatility indicator. This stocks Average True Range (ATR) is currently standing at 4.39.

Vir Biotechnology (VIR) stock Trading Summary:

Vir Biotechnology (VIR) stock changed position at -1.54% to closing price of $30.08 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Wednesday volume of 944495 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 1.11M shares and relative volume is now at 0.85.

Vir Biotechnology (VIR):

If you are considering getting into the day trading or penny stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of Vir Biotechnology (VIR) regarding latest trading session and presents some other indicators that can help you to support yours research about Vir Biotechnology (VIR).

Vir Biotechnology (VIR) Stock Price Movement in past 50 Days period and 52-Week period

Vir Biotechnology (VIR) stock demonstrated 158.19% move opposition to 12-month low and unveiled a move of -59.89% versus to 12-month high. The recent trading activity has given its price a change of -59.89% to its 50 Day High and 86.95% move versus to its 50 Day Low. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

Vir Biotechnology (VIR) Stock Past Performance

Vir Biotechnology (VIR) stock revealed -17.84% return for the recent month and disclosed 81.86% return in 3-month period. The stock grabbed 108.74% return over last 6-months. To measure stock performance since start of the year, it resulted a change of 139.20%. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Overbought and Oversold levels

The stock has RSI reading of 49.6. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

Analyst Watch: Analysts have assigned their consensus opinion on this stock with rating of 3.2 on scale of 1 to 5. 1 or 2 =>Buy view 4 or 5 => Sell opinion. 3 =>Hold. Analysts recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions.

Go here to read the rest:
Vir Biotechnology (VIR): Stock on the Move - Investor Welcome

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market Overview by 2026: Verified Market Research – Cole of Duty

April 23rd, 2020 1:46 pm

Shire

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=002

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Nanoparticles in Biotechnology and Pharmaceuticals sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Nanoparticles in Biotechnology and Pharmaceuticals sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Nanoparticles in Biotechnology and Pharmaceuticals sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Nanoparticles in Biotechnology and Pharmaceuticals market and formulate optimal business strategies to maximize market growth.

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Nanoparticles in Biotechnology and Pharmaceuticals market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Nanoparticles in Biotechnology and Pharmaceuticals market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Nanoparticles in Biotechnology and Pharmaceuticals Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Read this article:
Nanoparticles in Biotechnology and Pharmaceuticals Market Overview by 2026: Verified Market Research - Cole of Duty

Read More...

Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors – Yahoo Finance

April 23rd, 2020 1:46 pm

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Companys Board of Directors.

"Julie is an accomplished biotechnology executive who brings extensive oncology clinical drug development expertise to our Board of Directors," said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. "As we continue to advance AO-176 in clinical development for select solid tumors and plan for additional indications in hematologic malignancies including multiple myeloma, I am thrilled to have Julie join the Board of Directors. We share a deep commitment to developing novel therapies for patients with cancer and I look forward to working with her."

Julie Hambleton, M.D., Chief Medical Officer at IDEAYA Biosciences and Director for Arch Oncology, added, "I am very encouraged by the growing body of preclinical data, the clinical progress, and future clinical potential of AO-176. This novel anti-CD47 antibody has a best-in-class profile and I look forward to sharing my insights gained over 20 years in drug development to guide ongoing and future potential opportunities for AO-176 in across various oncology indications."

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton serves as Chief Medical Officer of IDEAYA Biosciences. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director,Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

In addition, Dr. Hambleton serves as a Director on IGM Biosciences Board of Directors.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with select solid tumors and hematologic malignancies, including multiple myeloma. The Companys next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncologys lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of antibody pipeline programs for the treatment cancer. For more information please visit http://www.archoncology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005212/en/

Contacts

Amy Figueroa, CFAFor Arch Oncologyafigueroa@archoncology.com 650-823-2704

Continued here:
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors - Yahoo Finance

Read More...

Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? – InvestorsObserver

April 23rd, 2020 1:45 pm

The 75 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 87 percent of stocks in the Biotechnology industry, CARAs 75 overall rating means the stock scores better than 75 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cara Therapeutics Inc (CARA) stock is trading at $15.81 as of 11:14 AM on Wednesday, Apr 22, a rise of $0.39, or 2.53% from the previous closing price of $15.42. The stock has traded between $15.29 and $16.44 so far today. Volume today is below average. So far 328,715 shares have traded compared to average volume of 541,813 shares.

To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.

Read more:
Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? - InvestorsObserver

Read More...

Page 583«..1020..582583584585..590600..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick